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Fu
rth
er
read
in
g
o
n
M
elan
o
co
rtin
recep
to
rs
C
aruso
V
etal.(2014)Syn
aptic
ch
an
ges
in
duced
by
m
elan
ocortin
sign
allin
g.N
at.Rev.N
eurosci.15
:
98-110
[PM
ID
:24588018]
Foord
SM
etal.(2005)In
tern
ation
alU
n
ion
ofPh
arm
acology.X
LV
I.G
protein
-coupled
receptor
list.
Pharm
acolRev
57
:279-288
[PM
ID
:15914470]
R
en
quist
BJ
et
al.
(2011)
Ph
ysiologicalroles
of
th
e
m
elan
ocortin
M
C
_3
receptor.
Eur.
J.Pharm
acol.
660
:13-20
[PM
ID
:21211527]
M
elatonin
receptors
G
protein
-coupled
receptors→
M
elaton
in
receptors
O
verview
:M
elaton
in
receptors
(n
o
m
en
clatu
re
as
ag
reed
b
y
th
e
N
C
-IU
P
H
A
R
Su
b
co
m
m
ittee
o
n
M
elato
n
in
R
ecep
to
rs
[474])are
activated
by
th
e
en
dogen
ous
ligan
ds
m
elaton
in
an
d
clin
ically
used
drugs
like
ram
elteon
an
d
agom
elatin
e.
N
om
enclature
M
T
1
receptor
M
T
2
receptor
H
G
N
C
,U
niProt
M
TN
R1A,P48039
M
TN
R1B,P49286
Endogenous
agonists
m
elatonin
[70,473,475]
m
elatonin
[70,473,475]
Agonists
ram
elteon
[954],agom
elatine
[70,136]
agom
elatine
[70,136],ram
elteon
[954,1636]
Selective
agonists
–
U
C
M
1014
[1855],IIK7
[532,1888],5-m
ethoxy-luzindole
(Partialagonist)
[475]
Selective
antagonists
–
4P-PD
O
T
(pK
i 8.8–9.4)
[70,475,476],K185
(pK
i 9.3)
[532,1888],D
H
97
(pK
i 8)
[1939]
Labelled
ligands
[ 125I]SD
6
(Agonist)
[1138],2-[ 125I]m
elatonin
(Agonist)
[70,475],
[ 3H
]m
elatonin
(Agonist)
[235]
[ 125I]SD
6
(Agonist)
[1138],2-[ 125I]m
elatonin
(Agonist)
[70,475],[ 125I]D
IV880
(Agonist,Partialagonist)
[1138],[ 3H
]m
elatonin
(Agonist)
[235]
C
o
m
m
en
ts:
m
elaton
in
,
2-iodo-m
elaton
in
,
agom
elatin
e,
G
R
196429,
LY
156735
an
d
ram
elteon
[954]
are
n
on
selective
agon
ists
for
M
T
1
an
d
M
T
2
receptors.
(-)-A
M
M
TC
displays
an
˜400-fold
greater
agon
ist
poten
cy
th
an
(+)-A
M
M
TC
at
rat
M
T
1
receptors
(see
A
M
M
TC
for
structure)
[1966].
Luzin
dole
is
an
M
T
1 /M
T
2
n
on
-selective
com
petitive
m
elaton
in
receptor
an
tago-
n
ist
w
ith
about
15-25
fold
selectivity
for
th
e
M
T
2
receptor
[476].
M
T
1 /M
T
2
h
eterodim
erspresen
tdifferen
tph
arm
acologicalprofiles
from
M
T
1
an
d
M
T
2
receptors
[75].
Th
e
M
T
3
bin
din
g
site
of
h
am
ster
brain
an
d
periph
eral
tissues
such
as
kidn
ey
an
d
testis,
also
term
ed
th
e
M
L
2
receptor,
bin
ds
selectively
2-iodo-[ 125I]5M
C
A
-N
A
T
[1356].
Ph
arm
acological
in
-
vestigation
s
of
M
T
3
bin
din
g
sites
h
ave
prim
arily
been
con
-
ducted
in
h
am
ster
tissues.
A
t
th
is
site,
Th
e
en
dogen
ous
ligan
d
N
-acetylseroton
in
[495,1215,1356,1588]an
d
5M
C
A
-N
A
T
[1588]
appear
to
fun
ction
as
agon
ists,w
h
ile
prazosin
[1215]fun
ction
s
as
an
an
tagon
ist.
Th
e
M
T
3
bin
din
g
site
of
h
am
ster
kidn
ey
w
as
also
iden
tified
as
th
e
h
am
ster
h
om
ologue
of
h
um
an
quin
on
e
reduc-
tase
2
(N
Q
O
2,
P16083
[1474,
1475]).
Th
e
M
T
3
bin
din
g
site
acti-
vated
by
5M
C
A
-N
A
T
in
eye
ciliary
body
is
positively
coupled
to
aden
ylyl
cyclase
an
d
regulates
ch
loride
secretion
[842].
X
enopus
m
elan
oph
ores
an
d
ch
ick
brain
express
a
distin
ct
receptor
(x420,
P49219;c346,P49288,in
itially
term
ed
M
el1C
)coupled
to
th
e
G
i/o
fam
ily
ofG
protein
s,forw
h
ich
G
PR
50
h
asrecen
tly
been
suggested
to
be
a
m
am
m
alian
coun
terpart
[479]
alth
ough
m
elaton
in
does
n
otbin
d
to
G
PR
50
receptors.Severalvarian
ts
ofth
e
M
T
N
R1B
gen
e
h
ave
been
associated
w
ith
in
creased
type
2
diabetes
risk.
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Fu
rth
er
read
in
g
o
n
M
elato
n
in
recep
to
rs
D
ubocovich
M
L
et
al.
(2010)
In
tern
ation
al
U
n
ion
of
Basic
an
d
C
lin
ical
Ph
arm
acology.
LX
X
V.
N
om
en
clature,
classification
,
an
d
ph
arm
acology
of
G
protein
-coupled
m
elaton
in
receptors.
Pharm
acol.Rev.62
:343-80
[PM
ID
:20605968]
Jockers
R
et
al.
(2016)
U
pdate
on
m
elaton
in
receptors:
IU
PH
A
R
R
eview
20.
Br.
J.Pharm
acol.
173
:
2702-25
[PM
ID
:27314810]
Liu
J
et
al.
(2016)
M
T1
an
d
M
T2
M
elaton
in
R
eceptors:
A
Th
erapeutic
Perspective.
A
nnu.
Rev.
Phar-
m
acol.Toxicol.56
:361-83
[PM
ID
:26514204]
Zlotos
D
P
etal.(2013)
M
T1
an
d
M
T2
M
elaton
in
R
eceptors:Ligan
ds,M
odels,O
ligom
ers,an
d
Th
er-
apeutic
Poten
tial.
J.M
ed.C
hem
.[PM
ID
:24228714]
M
etabotropic
glutam
ate
receptors
G
protein
-coupled
receptors→
M
etabotropic
glutam
ate
receptors
O
verview
:
M
etabotropic
glutam
ate
(m
G
lu)
receptors
(n
o
m
en
-
clatu
re
as
ag
reed
b
y
th
e
N
C
-IU
P
H
A
R
Su
b
co
m
m
ittee
o
n
M
etab
o
tro
p
ic
G
lu
tam
ate
R
ecep
to
rs
[1743])
are
a
fam
ily
of
G
-protein
coupled
receptors
activated
by
th
e
n
eurotran
sm
it-
ter
glutam
ate.
Th
e
m
G
lu
fam
ily
is
com
posed
of
eigh
t
m
em
bers
(n
am
ed
m
G
lu1
to
m
G
lu8)w
h
ich
are
divided
in
th
ree
groupsbased
on
sim
ilarities
of
agon
ist
ph
arm
acology,prim
ary
sequen
ce
an
d
G
protein
couplin
g
to
effector:G
roup-I(m
G
lu
1
an
d
m
G
lu
5 ),G
roup-
II(m
G
lu
2
an
d
m
G
lu
3 )an
d
G
roup-III(m
G
lu
4 ,m
G
lu
6 ,m
G
lu
7
an
d
m
G
lu
8 )
(see
Furth
er
readin
g).
Structurally,
m
G
lu
are
com
posed
of
th
ree
juxtaposed
dom
ain
s:
a
core
G
-protein
-activatin
g
seven
-tran
sm
em
bran
e
dom
ain
(TM
),
com
m
on
to
all
G
PC
R
s,
is
lin
ked
via
a
rigid
cystein
e-rich
dom
ain
(C
R
D
)
to
th
e
V
en
us
Flytrap
dom
ain
(V
FTD
),
a
large
bi-lobed
ex-
tracellular
dom
ain
w
h
ere
glutam
ate
bin
ds.
Th
e
structures
of
th
e
V
FTD
of
m
G
lu
1 ,
m
G
lu
2 ,
m
G
lu
3 ,
m
G
lu
5
an
d
m
G
lu
7
h
ave
been
solved
[1075,
1364,
1408,
1984].
Th
e
structure
of
th
e
7
tran
s-
m
em
bran
e
(TM
)
dom
ain
s
of
both
m
G
lu1
an
d
m
G
lu5
h
ave
been
solved,an
d
con
firm
a
gen
eralh
elicalorgan
ization
sim
ilar
to
th
at
of
oth
er
G
PC
R
s,
alth
ough
th
e
h
elices
appear
m
ore
com
pacted
[465,2136].m
G
lu
form
con
stitutive
dim
erscrosslin
ked
by
a
disul-
fide
bridge.
A
lth
ough
m
G
lu
receptors
h
ave
been
th
ough
t
to
on
ly
form
h
om
odim
ers,recen
t
studies
revealed
th
e
possible
form
ation
of
h
eterodim
ers
betw
een
eith
er
group-I
receptors,
or
w
ith
in
an
d
betw
een
group-II
an
d
-III
receptors
[468].
A
lth
ough
w
ell
ch
arac-
terized
in
tran
sfected
cells,co-localization
an
d
specific
ph
arm
aco-
logicalproperties
also
suggest
th
e
existen
ce
of
such
h
eterodim
ers
in
th
e
brain
[2183].
Th
e
en
dogen
ous
ligan
ds
of
m
G
lu
are
L-glutam
ic
acid,
L-serin
e-O
-ph
osph
ate,
N
-acetylaspartylglutam
ate
(N
A
A
G
)
an
d
L-cystein
e
sulph
in
ic
acid.
G
roup-I
m
G
lu
receptors
m
ay
be
ac-
tivated
by
3,5-D
H
PG
an
d
(S)-3H
PG
[204]
an
d
an
tagon
ized
by
(S)-h
exylh
om
oiboten
ic
acid
[1235].G
roup-IIm
G
lu
receptors
m
ay
be
activated
by
LY
389795
[1365],
LY
379268
[1365],
eglum
egad
[1744,
2138],
D
C
G
-IV
an
d
(2R,3R)-A
PD
C
[1745],
an
d
an
tago-
n
ised
by
eG
lu
[890]
an
d
LY
307452
[518,
2096].
G
roup-III
m
G
lu
receptors
m
ay
be
activated
by
L-A
P4
an
d
(R,S)-4-PPG
[610].A
n
ex-
am
ple
of
an
an
tagon
ist
selective
for
m
G
lu
receptors
is
LY
341495,
w
h
ich
blocks
m
G
lu
2
an
d
m
G
lu
3
at
low
n
an
om
olar
con
cen
tra-
tion
s,
m
G
lu
8
at
h
igh
n
an
om
olar
con
cen
tration
s,
an
d
m
G
lu
4 ,
m
G
lu
5 ,
an
d
m
G
lu
7
in
th
e
m
icrom
olar
ran
ge
[1001].
In
addition
to
orth
osteric
ligan
ds
th
at
directly
in
teract
w
ith
th
e
glutam
ate
recogn
ition
site,
allosteric
m
odulators
th
at
bin
d
w
ith
in
th
e
TM
dom
ain
h
ave
been
described.
N
egative
allosteric
m
odulators
are
listed
separately.
Th
e
positive
allosteric
m
odulators
m
ost
often
act
as
‘poten
tiators’
of
an
orth
osteric
agon
ist
respon
se,
w
ith
out
sign
ifican
tly
activatin
g
th
e
receptor
in
th
e
absen
ce
of
agon
ist.
N
om
enclature
m
G
lu
1
receptor
m
G
lu
2
receptor
m
G
lu
3
receptor
m
G
lu
4
receptor
m
G
lu
5
receptor
H
G
N
C
,U
niProt
G
RM
1,Q
13255
G
RM
2,Q
14416
G
RM
3,Q
14832
G
RM
4,Q
14833
G
RM
5,P41594
Endogenous
agonists
L-glutam
ic
acid
[1574]
L-glutam
ic
acid
[1574]
L-glutam
ic
acid
[1574],
N
AAG
[1750]
L-glutam
ic
acid
[1574]
L-glutam
ic
acid
[1574]
Agonists
–
–
–
L-AP4
[2138],
L-serine-O
-phosphate
[2138]
–
Selective
agonists
–
–
–
LSP4-2022
[666]
(S)-(+)-C
BPG
(Partialagonist)
[1261]
–
Rat,C
H
PG
[1407]
Antagonists
LY367385
(pIC
50
5.1)
[364]
–
–
M
AP4
(pK
i 4.6)
[721]–
Rat
–
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w
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(continued)
N
om
enclature
m
G
lu
1
receptor
m
G
lu
2
receptor
m
G
lu
3
receptor
m
G
lu
4
receptor
m
G
lu
5
receptor
Selective
antagonists
3-M
ATID
A
(pIC
50
5.2)
[1386]–
Rat,
(S)-(+)-C
BPG
(pIC
50
4.2)
[1261]–
Rat,(S)-TBPG
(pIC
50
4.2)[381]–
Rat,
AID
A
(pA
2
4.2)
[1387]
PC
C
G
-4
(pIC
50
5.1)
[1551]–
Rat
–
–
AC
D
PP
(pIC
50
6.9)
[186]
Allosteric
m
odulators
–
C
BiPES
(Positive)
(pEC
50
7)
[917],4-M
PPTS
(Positive)
(pIC
50
5.8)
[100,916,917,
1731]
–
SIB-1893
(Positive)
(pEC
50
6.3–6.8)
[1281],M
PEP
(Positive)
(pEC
50
6.3–6.6)
[1281],PH
C
C
C
(Positive)
(pEC
50
4.5)
[1247]
3,3’-difluorobenzaldazine
(Positive)
(pIC
50
5.6–8.5)
[1481,1482],
allosw
itch-1
(N
egative)
(pIC
50
8.1)
[1583]–
Rat,C
D
PPB
(Positive)
(pEC
50
7.6–8)
[1002,1180],M
TEP
(N
egative)
(pK
i 7.8)
[228],M
PEP
(N
egative)
(pIC
50
7.4–7.7)
[609,
611],fenobam
(N
egative)
(pIC
50
7.2)
[1592],SIB-1893
(N
egative)
(pIC
50
5.9–6.5)
[609,2028],
SIB-1757
(N
egative)
(pIC
50
6–6.4)
[609,2028],C
PPH
A
(Positive)
(pIC
50
6.3)
[1482]
Selective
allosteric
m
odulators
BAY
367620
(N
egative)
(pK
i 9.5)
[279]–
Rat,JN
J16259685
(N
egative)
(pIC
50
8.9)
[1104],Ro01-6128
(Positive)
(pK
i 7.5–7.7)
[1019]–
Rat,
LY456236
(N
egative)
(pIC
50
6.9)
[1160],C
PC
C
O
Et
(N
egative)
(pIC
50
5.2–5.8)
[1183]
Ro64-5229
(N
egative)
(pIC
50
7)
[1031]–
Rat,
biphenylindanone
A
(Positive)
(pEC
50
7)
[187]
–
VU
0361737
(Positive)
(pEC
50
6.6)
[508],
VU
0155041
(Positive)
(pEC
50
6.1)
[1468]
VU
-1545
(Positive)
(pEC
50
8)
[429]
N
om
enclature
m
G
lu
6
receptor
m
G
lu
7
receptor
m
G
lu
8
receptor
H
G
N
C
,U
niProt
G
RM
6,O
15303
G
RM
7,Q
14831
G
RM
8,O
00222
Endogenous
agonists
L-glutam
ic
acid
[1574]
L-glutam
ic
acid
[1574]
L-serine-O
-phosphate
[1254,2138],L-glutam
ic
acid
[1574]
Agonists
–
LSP4-2022
[666],L-serine-O
-phosphate
[2138],L-AP4
[2138]
(S)-3,4-D
C
PG
[1952],L-AP4
[1254]
Selective
agonists
1-benzyl-APD
C
[1987]–
Rat,hom
o-AM
PA
[244]
–
–
Antagonists
M
AP4
(pIC
50
3.5)
[1575]–
Rat,TH
PG
[1956]
–
M
PPG
(pIC
50
4.3)
[2138]
Allosteric
m
odulators
–
M
M
PIP
(N
egative)
(pIC
50
6.1–7.6)
[1467,1900]–
Rat,AD
X
71743
(N
egative)
(pIC
50
7.2)
[938],AM
N
082
(Positive)
(pEC
50
6.5–6.8)
[1349],X
AP044
(N
egative)
(pIC
50
5.6)
[618]
–
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C
o
m
m
en
ts:Th
e
activity
of
N
A
A
G
as
an
agon
ist
at
m
G
lu
3
recep-
tors
w
as
question
ed
on
th
e
basis
ofcon
tam
in
ation
w
ith
glutam
ate
[341,576],but
th
is
h
as
been
refuted
[1430].
R
adioligan
d
bin
din
g
usin
g
a
variety
of
radioligan
ds
h
as
been
con
ducted
on
recom
bin
an
t
receptors
(for
exam
ple,
[ 3H
]R
214127
[1103]
an
d
[ 3H
]Y
M
298198
[1025]
at
m
G
lu
1
receptors
an
d
[ 3H
]M
-M
PEP
[609]an
d
[ 3H
]m
eth
oxym
eth
yl-M
TEP
[48]at
m
G
lu
5
receptors.
A
lth
ough
a
n
um
ber
of
radioligan
ds
h
ave
been
used
to
exam
in
e
bin
din
g
in
n
ative
tissues,
correlation
w
ith
in
divid-
ual
subtypes
is
lim
ited.
M
an
y
ph
arm
acological
agen
ts
h
ave
n
ot
been
fully
tested
across
allkn
ow
n
subtypes
ofm
G
lu
receptors.Po-
ten
tial
differen
ces
lin
ked
to
th
e
species
(e.g.
h
um
an
versus
rat
or
m
ouse)
of
th
e
receptors
an
d
th
e
receptor
splice
varian
ts
are
gen
-
erally
n
ot
kn
ow
n
.
Th
e
in
fluen
ce
of
receptor
expression
level
on
ph
arm
acology
an
d
selectivity
h
as
n
ot
been
con
trolled
for
in
m
ost
studies,particularly
th
ose
in
volvin
g
fun
ction
alassays
of
receptor
couplin
g.
(S)-(+)-C
BPG
is
an
an
tagon
ist
at
m
G
lu
1 ,
but
is
an
agon
ist
(albeit
of
reduced
efficacy)
at
m
G
lu
5
receptors.
D
C
G
-IV
also
exh
ibits
agon
ist
activity
at
N
M
D
A
glutam
ate
receptors
[2007],
an
d
is
an
an
tagon
ist
at
all
G
roup-III
m
G
luR
s
w
ith
an
IC
50
of
30µ
M
.
A
poten
tial
n
ovel
m
etabotropic
glutam
ate
receptor
coupled
to
ph
osph
oin
ositide
turn
over
h
as
been
observed
in
ratbrain
;itis
ac-
tivated
by
4-m
eth
ylh
om
oiboten
ic
acid
(in
effective
as
an
agon
ist
at
recom
bin
an
t
G
roup
Im
etabotropic
glutam
ate
receptors),but
is
resistan
t
to
LY
341495
[356].
Th
ere
are
also
reports
of
a
distin
ct
m
etabotropic
glutam
ate
receptor
coupled
to
ph
osph
olipase
D
in
rat
brain
,w
h
ich
does
n
ot
readily
fit
in
to
th
e
curren
t
classification
[1013,1549]
A
related
class
C
receptorcom
posed
oftw
o
distin
ctsubun
its,T1R
1
+
T1R
3
is
also
activated
by
glutam
ate
an
d
is
respon
sible
forum
am
i
taste
detection
.
A
ll
selective
an
tagon
ists
at
m
etabotropic
glutam
ate
receptors
are
com
petitive.
Fu
rth
er
read
in
g
o
n
M
etab
o
tro
p
ic
g
lu
tam
ate
recep
to
rs
C
on
n
PJetal.(1997)Ph
arm
acology
an
d
fun
ction
s
ofm
etabotropic
glutam
ate
receptors.
A
nnu.Rev.
Pharm
acol.Toxicol.37
:205-237
[PM
ID
:9131252]
Ferraguti
F
et
al.
(2006)
M
etabotropic
glutam
ate
receptors.
C
ell
T
issue
Res.
326
:
483-504
[PM
ID
:16847639]
N
icoletti
F
et
al.
(2011)
M
etabotropic
glutam
ate
receptors:
from
th
e
w
orkben
ch
to
th
e
bedside.
N
europharm
acology
60
:1017-41
[PM
ID
:21036182]
N
isw
en
der
C
M
etal.(2010)M
etabotropic
glutam
ate
receptors:ph
ysiology,ph
arm
acology,an
d
dis-
ease.A
nnu.Rev.Pharm
acol.Toxicol.50
:295-322
[PM
ID
:20055706]
Pin
JP
et
al.
(2016)
O
rgan
ization
an
d
fun
ction
s
of
m
G
lu
an
d
G
A
BA
B
receptor
com
plexes.
N
ature
540
:60-68
[PM
ID
:27905440]
R
on
dard
P
et
al.
(2011)
Th
e
com
plexity
of
th
eir
activation
m
ech
an
ism
open
s
n
ew
possibilities
for
th
e
m
odulation
of
m
G
lu
an
d
G
A
BA
B
class
C
G
protein
-coupled
receptors.
N
europharm
acology
60
:82-92
[PM
ID
:20713070]
M
otilin
receptor
G
protein
-coupled
receptors→
M
otilin
receptor
O
verview
:
M
otilin
receptors
(p
ro
visio
n
al
n
o
m
en
clatu
re)
are
activated
by
m
otilin
(M
LN
,
P12872),
a
22
am
in
o-acid
peptide
derived
from
a
precursor
(M
LN
,
P12872),
w
h
ich
m
ay
also
gen
erate
a
m
otilin
-associated
peptide
(M
LN
,P12872).Th
ese
receptors
prom
ote
gastroin
testin
alm
otility
an
d
are
suggested
to
be
respon
sible
for
th
e
gastroin
testin
alprokin
etic
effects
of
certain
m
acrolide
an
tibiotics
(often
called
m
otilides;e.g.eryth
rom
ycin
),alth
ough
for
m
an
y
of
th
ese
m
olecules
th
e
eviden
ce
is
sparse.
N
om
enclature
m
otilin
receptor
H
G
N
C
,U
niProt
M
LN
R,O
43193
Endogenous
agonists
m
otilin
(M
LN
,P12872)
[386,1286,1287,1288]
Agonists
alem
cinal[1947],erythrom
ycin-A
[533,1947],azithrom
ycin
[225]
Selective
agonists
cam
icinal[105,1712],m
item
cinal[1023,1918]–
Rabbit
Selective
antagonists
M
A-2029
(pA
2
9.2)
[1884],G
M
-109
(pIC
50
8)
[736]–
Rabbit
Labelled
ligands
[ 125I]m
otilin
(hum
an)
(Agonist)
[533]
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C
o
m
m
en
ts:
In
term
s
of
structure,th
e
m
otilin
receptor
h
as
clos-
esth
om
ology
w
ith
th
e
gh
relin
receptor.Th
us,th
e
h
um
an
m
otilin
receptor
sh
ares
52%
overall
am
in
o
acid
iden
tity
w
ith
th
e
gh
re-
lin
receptor
an
d
86%
in
th
e
tran
sm
em
bran
e
region
s
[759,
1918,
1947].
H
ow
ever,
differen
ces
betw
een
th
e
N
-term
in
us
region
s
of
th
ese
receptors
m
ean
s
th
at
th
eir
cogn
ate
peptide
ligan
ds
do
n
ot
readily
activate
each
oth
er
[408,1712].In
laboratory
roden
ts,th
e
gen
e
en
codin
g
th
e
m
otilin
percursor
appears
to
be
absen
t,
w
h
ile
th
e
receptor
appears
to
be
a
pseudogen
e
[759,
1710].
Fun
ction
s
of
m
otilin
(M
LN
,P12872)
are
n
ot
usually
detected
in
roden
ts,al-
th
ough
brain
an
d
oth
er
respon
ses
to
m
otilin
an
d
th
e
m
acrolide
alem
cin
al
h
ave
been
reported
an
d
th
e
m
ech
an
ism
of
th
ese
ac-
tion
s
is
obscure
[1311,
1462].
N
otably,
in
som
e
n
on
-laboratory
roden
ts
(e.g.
th
e
N
orth
A
m
erican
kan
garoo
rat
(D
ipodom
ys)
an
d
m
ouse
(M
icrodipodops)
a
fun
ction
alform
of
m
otilin
m
ay
exist
but
th
e
m
otilin
receptor
is
n
on
-fun
ction
al[1159].M
arked
differen
ces
in
ligan
d
affin
ities
for
th
e
m
otilin
receptor
in
dogs
an
d
h
um
an
s
m
ay
be
explain
ed
by
sign
ifican
t
differen
ces
in
receptor
structure
[1711].N
ote
th
atforth
e
com
plex
m
acrolide
structures,selectivity
of
action
h
as
often
n
ot
been
rigorously
exam
in
ed
an
d
oth
er
ac-
tion
s
are
possible
(e.g.
P2X
in
h
ibition
by
eryth
rom
ycin
;
[2216]).
Sm
allm
olecule
m
otilin
receptoragon
istsare
n
ow
described
[1159,
1712,2100].Th
e
m
otilin
receptor
does
n
otappear
to
h
ave
con
sti-
tutive
activity
[812].A
lth
ough
n
otproven
,th
e
existen
ce
ofbiased
agon
ism
at
th
e
receptor
h
as
been
suggested
[1288,1348,1709].A
trun
cated
5-tran
sm
em
bran
e
structure
h
as
been
iden
tified
but
th
is
is
w
ith
out
activity
w
h
en
tran
sfected
in
to
a
h
ost
cell[533].
R
ecep-
tor
dim
erisation
h
as
n
ot
been
reported.
Fu
rth
er
read
in
g
o
n
M
o
tilin
recep
to
r
D
e
Sm
etB
etal.(2009)M
otilin
an
d
gh
relin
as
prokin
etic
drug
targets.Pharm
acol.T
her.123
:207-23
[PM
ID
:19427331]
San
ger
G
J
et
al.
(2016)
G
h
relin
an
d
m
otilin
receptors
as
drug
targets
for
gastroin
testin
aldisorders.
N
atRev
G
astroenterolH
epatol13
:38-48
[PM
ID
:26392067]
N
eurom
edin
U
receptors
G
protein
-coupled
receptors→
N
eurom
edin
U
receptors
O
verview
:
N
eurom
edin
U
receptors
(p
ro
visio
n
al
n
o
m
en
-
clatu
re
as
reco
m
m
en
d
ed
b
y
N
C
-IU
P
H
A
R
[557])
are
acti-
vated
by
th
e
en
dogen
ous
25
am
in
o
acid
peptide
n
eurom
edin
U
(n
eurom
edin
U
-25
(N
M
U
,P48645),N
m
U
-25),a
peptide
origin
ally
isolated
from
pig
spin
alcord
[1344].In
h
um
an
s,N
m
U
-25
appears
to
be
th
e
sole
productofa
precursorgen
e
(N
M
U
,P48645)sh
ow
in
g
a
broad
tissue
distribution
,but
w
h
ich
is
expressed
at
h
igh
est
lev-
els
in
th
e
uppergastroin
testin
altract,C
N
S,bon
e
m
arrow
an
d
fetal
liver.
M
uch
sh
orter
version
s
of
N
m
U
are
foun
d
in
som
e
species,
butn
otin
h
um
an
,an
d
are
derived
atleastin
som
e
in
stan
ces
from
th
e
proteolytic
cleavage
ofth
e
lon
gerN
m
U
.D
espite
species
differ-
en
ces
in
N
m
U
structure,
th
e
C
-term
in
al
region
(particularly
th
e
C
-term
in
al
pen
tapeptide)
is
h
igh
ly
con
served
an
d
con
tain
s
bio-
logicalactivity.N
eurom
edin
S
(n
eurom
edin
S-33
(N
M
S,Q
5H
8A
3))
h
as
also
been
iden
tified
as
an
en
dogen
ous
agon
ist
[1378].
N
m
S-
33
is,as
its
n
am
e
suggests,a
33
am
in
o-acid
product
ofa
precursor
protein
derived
from
a
sin
gle
gen
e
an
d
con
tain
s
an
am
idated
C
-
term
in
alh
eptapeptide
iden
ticalto
N
m
U
.N
m
S-33
appears
to
acti-
vate
N
M
U
receptors
w
ith
equivalen
t
poten
cy
to
N
m
U
-25.
N
om
enclature
N
M
U
1
receptor
N
M
U
2
receptor
H
G
N
C
,U
niProt
N
M
U
R1,Q
9H
B89
N
M
U
R2,Q
9G
ZQ
4
Antagonists
–
R-PSO
P
(pK
B
7)
[1193]
C
o
m
m
en
ts:
N
M
U
1
an
d
N
M
U
2
couple
predom
in
an
tly
to
G
q/11
alth
ough
th
ere
is
eviden
ce
of
good
couplin
g
to
G
i/o
[218,825,833].
N
M
U
1
an
d
N
M
U
2
can
be
labelled
w
ith
[ 125I]-N
m
U
an
d
[ 125I]-N
m
S
(of
various
species,e.g.
[1319]),BO
D
IPY
®
TM
R
-N
M
U
or
C
y3B-N
M
U
-8
[218].
A
ran
ge
of
radiolabelled
( 125I-),fluorescen
tly
labelled
(e.g.
C
y3,C
y5,rh
odam
in
e
an
d
FA
M
)
an
d
biotin
labelled
version
s
of
n
eurom
edin
U
-25
(N
M
U
,P48645)
an
d
n
eurom
edin
S-33
(N
M
S,Q
5H
8A
3)
are
n
ow
com
m
ercially
available.
Searchable
database:http://w
w
w.guidetopharm
acology.org/index.jsp
N
eurom
edin
U
receptors
S89
FullC
ontents
ofC
onciseG
uide:http://onlinelibrary.w
iley.com
/doi/10.1111/bph.13878/full
S.P.H.Alexanderetal.The
Concise
Guide
to
PHARM
ACOLOGY
2017/18:G
protein-coupled
receptors.British
JournalofPharm
acology
(2017)174,S17–S129
Fu
rth
er
read
in
g
o
n
N
eu
ro
m
ed
in
U
recep
to
rs
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PJ
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(2004)
N
eurom
edin
U
an
d
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receptors:
structure,
fun
ction
,
an
d
ph
ysiological
roles.
Pharm
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[PM
ID
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Budh
iraja
S
etal.(2009)N
eurom
edin
U
:ph
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arm
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an
d
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poten
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Fun-
dam
C
lin
Pharm
acol23
:149-57
[PM
ID
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M
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Em
ergin
g
ph
arm
acology
an
d
ph
ysiology
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n
eurom
edin
U
an
d
th
e
struc-
turally
related
peptide
n
eurom
edin
S.Br.J.Pharm
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[PM
ID
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N
ovak
C
M
.(2009)
N
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N
europeptide
FF/neuropeptide
AF
receptors
G
protein
-coupled
receptors→
N
europeptide
FF/n
europeptide
A
F
receptors
O
verview
:
Th
e
N
europeptide
FF
receptor
fam
ily
con
tain
s
tw
o
subtypes,
N
PFF1
an
d
N
PFF2
(p
ro
visio
n
al
n
o
m
en
clatu
re
[557]),
w
h
ich
exh
ibit
h
igh
affin
ities
for
n
europeptide
FF
(N
PFF,
O
15130)an
d
R
Fam
ide
related
peptides(R
FR
P:precursorgen
e
sym
-
bol
N
PV
F,Q
9H
C
Q
7).
N
PFF1
is
broadly
distributed
in
th
e
cen
tral
n
ervous
system
w
ith
th
e
h
igh
estlevels
foun
d
in
th
e
lim
bic
system
an
d
th
e
h
ypoth
alam
us.N
PFF2
is
presen
tin
h
igh
den
sity
in
th
e
su-
perficiallayers
ofth
e
m
am
m
alian
spin
alcord
w
h
ere
it
is
in
volved
in
n
ociception
an
d
m
odulation
of
opioid
fun
ction
s.
N
om
enclature
N
PFF1
receptor
N
PFF2
receptor
H
G
N
C
,U
niProt
N
PFFR1,Q
9G
ZQ
6
N
PFFR2,Q
9Y5X
5
Potency
orderofendogenous
ligands
RFRP-1
(N
PVF,Q
9H
C
Q
7)
>
RFRP-3
(N
PVF,Q
9H
C
Q
7)
>
FM
RFneuropeptide
FF
(N
PFF,
O
15130)
>
neuropeptide
AF
(N
PFF,O
15130)
>
neuropeptide
SF
(N
PFF,O
15130),
Q
RFP43
(Q
RFP,P83859),PrRP-31
(PRLH
,P81277)
[663]
neuropeptide
AF
(N
PFF,O
15130),neuropeptide
FF
(N
PFF,O
15130)
>
PrRP-31
(PRLH
,P81277)
>
FM
RF,Q
RFP43
(Q
RFP,P83859)
>
neuropeptide
SF
(N
PFF,O
15130)
[663]
Endogenous
agonists
neuropeptide
FF
(N
PFF,O
15130)
[663,664,1359],RFRP-3
(N
PVF,Q
9H
C
Q
7)
[664,665,
1359]
neuropeptide
FF
(N
PFF,O
15130)
[664,1358]
Selective
agonists
–
dN
PA
[1681],AC
263093
[1092]
Antagonists
RF9
(pK
i 7.2)
[1814]
–
Selective
antagonists
AC
262620
(pK
i 7.7–8.1)
[1092],AC
262970
(pK
i 7.4–8.1)
[1092]
–
Labelled
ligands
[ 125I]Y-RFRP-3
(Agonist)
[664],[ 3H
]N
PVF
(Agonist)
[1928],[ 125I]N
PFF
(Agonist)
[663]
[ 125I]EYF
(Agonist)
[1359],[ 3H
]EYF
(Agonist)
[1928],[ 125I]N
PFF
(Agonist)
[663]
C
o
m
m
en
ts:A
n
orph
an
receptor
G
PR83
(Q
9N
Y
M
4)sh
ow
s
sequen
ce
sim
ilarities
w
ith
N
PFF1,N
PFF2,PrR
P
an
d
Q
R
FP
receptors.Th
e
an
tagon
ist
R
F9
is
selective
for
N
PFF
receptors,but
does
n
ot
distin
guish
betw
een
th
e
N
PFF1
an
d
N
PFF2
subtypes
(pK
i 7.1
an
d
7.2,respectively,[1814]).
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eu
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e
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recep
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M
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L
et
al.
(2010)
O
pioid-m
odulatin
g
properties
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th
e
n
europeptide
FF
system
.
Biofactors
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:423-9
[PM
ID
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V
yas
N
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relation
sh
ips
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n
europeptide
FF
an
d
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peptidic
an
d
n
on
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[PM
ID
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Yan
g
H
Y
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M
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role
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n
europeptide
FF
system
in
n
ociception
an
d
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an
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:1-18
[PM
ID
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N
europeptide
S
receptor
G
protein
-coupled
receptors→
N
europeptide
S
receptor
O
verview
:Th
e
n
europeptide
S
receptor
(N
PS,p
ro
visio
n
al
n
o
m
en
clatu
re
[557])
respon
ds
to
th
e
20
am
in
o-acid
peptide
n
europeptide
S
derived
from
a
precursor
(N
PS,P0C
0P6).
N
om
enclature
N
PS
receptor
H
G
N
C
,U
niProt
N
PSR1,Q
6W
5P4
Endogenous
agonists
neuropeptide
S
(N
PS,P0C
0P6)
[2159]
Selective
agonists
PW
T1-N
PS
[1692]–
M
ouse
Selective
antagonists
N
C
G
C
84
(pA
2
9)
[1957],SH
A
68
(pA
2
8.1)
[1693]–
M
ouse,RTI-118
[2214]
Labelled
ligands
[ 125I]Tyr 10N
PS
(hum
an)
(Agonist)
[2159]
C
o
m
m
en
ts:
M
ultiple
sin
gle-n
ucleotide
polym
orph
ism
s
(SN
P)
an
d
severalsplice
varian
ts
h
ave
been
iden
tified
in
th
e
h
um
an
N
PS
receptor.
Th
e
m
ost
in
terestin
g
of
th
ese
is
an
A
sn
-Ile
exch
an
ge
at
position
107
(A
sn
107Ile).
Th
e
h
um
an
N
PS
receptor
A
sn
107Ile
dis-
played
sim
ilarbin
din
g
affin
ity
buth
igh
erN
PS
poten
cy
(by
approx.
10-fold)
th
an
h
um
an
N
PS
receptor
A
sn
107
[1645].
Several
epi-
dem
iological
studies
reported
an
association
betw
een
A
sn
107Ile
receptor
varian
t
an
d
susceptibility
to
pan
ic
disorders
[458,
460,
1506,
1621].
Th
e
SN
P
A
sn
107Ile
h
as
also
been
lin
ked
to
sleep
beh
avior
[662],in
flam
m
atory
bow
el
disease
[402],sch
izoph
ren
ia
[1145],in
creased
im
pulsivity
an
d
A
D
H
D
sym
ptom
s
[1083].In
ter-
estin
gly,a
carboxy-term
in
alsplice
varian
t
ofh
um
an
N
PS
receptor
w
as
foun
d
to
be
overexpressed
in
asth
m
atic
patien
ts
[1091].
Fu
rth
er
read
in
g
o
n
N
eu
ro
p
ep
tid
e
S
recep
to
r
G
uerrin
i
R
et
al.
(2010)
N
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an
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n
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S
an
d
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receptor.
M
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Rev
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[PM
ID
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X
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prom
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g
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an
d
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effects.
N
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[PM
ID
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N
europeptide
W
/neuropeptide
B
receptors
G
protein
-coupled
receptors→
N
europeptide
W
/n
europeptide
B
receptors
O
verview
:
Th
e
n
europeptide
BW
receptor
1
(N
PBW
1,
p
ro
-
visio
n
al
n
o
m
en
clatu
re
[557])
is
activated
by
tw
o
23-
am
in
o-acid
peptides,
n
europeptide
W
(n
europeptide
W
-23
(N
PW
,
Q
8N
729))
an
d
n
europeptide
B
(n
europeptide
B-23
(N
PB,
Q
8N
G
41))
[584,
1792].
C
-term
in
ally
exten
ded
form
s
of
th
e
pep-
tides
(n
europeptide
W
-30
(N
PW
,Q
8N
729)an
d
n
europeptide
B-29
(N
PB,Q
8N
G
41))also
activate
N
PBW
1
[216].U
n
ique
to
both
form
s
of
n
europeptide
B
is
th
e
N
-term
in
albrom
in
ation
of
th
e
first
tryp-
toph
an
residue,an
d
itis
from
th
is
post-tran
slation
alm
odification
th
at
th
e
n
om
en
clature
N
PB
is
derived.
Th
ese
peptides
w
ere
first
iden
tified
from
bovin
e
h
ypoth
alam
us
an
d
th
erefore
are
classed
as
n
europeptides.
En
dogen
ous
varian
ts
of
th
e
peptides
w
ith
-
out
th
e
N
-term
in
al
brom
in
ation
,des-Br-n
europeptide
B-23
(N
PB,
Q
8N
G
41)
an
d
des-Br-n
europeptide
B-29
(N
PB,
Q
8N
G
41),
w
ere
n
ot
foun
d
to
be
m
ajor
com
pon
en
ts
of
bovin
e
h
ypoth
alam
ic
tis-
sue
extracts.
Th
e
N
PBW
2
receptor
is
activated
by
th
e
sh
ort
an
d
C
-term
in
alexten
ded
form
s
of
n
europeptide
W
an
d
n
europeptide
B
[216].
N
om
enclature
N
PBW
1
receptor
N
PBW
2
receptor
H
G
N
C
,U
niProt
N
PBW
R1,P48145
N
PBW
R2,P48146
Potency
order
ofendogenous
ligands
neuropeptide
B-29
(N
PB,Q
8N
G
41)
>
neuropeptide
B-23
(N
PB,
Q
8N
G
41)
>
neuropeptide
W
-23
(N
PW
,Q
8N
729)
>
neuropeptide
W
-30
(N
PW
,Q
8N
729)
[216]
neuropeptide
W
-23
(N
PW
,Q
8N
729)
>
neuropeptide
W
-30
(N
PW
,Q
8N
729)
>
neuropeptide
B-29
(N
PB,Q
8N
G
41)
>
neuropeptide
B-23
(N
PB,Q
8N
G
41)
[216]
Selective
agonists
Ava3
[945],Ava5
[945]
–
Labelled
ligands
[ 125I]N
PW
-23
(hum
an)
(Agonist)
[1816]
[ 125I]N
PW
-23
(hum
an)
(Agonist)
[1792]
C
o
m
m
en
ts:
Poten
cy
m
easurem
en
ts
w
ere
con
ducted
w
ith
h
eterologously-expressed
receptors
w
ith
a
ran
ge
of
0.14-0.57
n
M
(N
PBW
1)
an
d
0.98-21
n
M
(N
PBW
2).
N
PBW
1
-/-
m
ice
sh
ow
ch
an
ges
in
social
beh
avior,
suggestin
g
th
at
th
e
N
PBW
1
path
w
ay
m
ay
h
ave
an
im
portan
t
role
in
th
e
em
otion
al
respon
ses
of
social
in
teraction
[1414].
For
a
review
of
th
e
con
tribution
of
n
europep-
tideB/W
to
socialdom
in
an
ce,see
[2080].Ith
as
been
reported
th
at
n
europeptide
W
m
ay
h
ave
a
key
role
in
th
e
gatin
g
ofstressfulstim
-
uliw
h
en
m
ice
are
exposed
to
n
ovelen
viron
m
en
ts
[1392].Tw
o
an
-
tagon
ists
h
ave
been
discovered
an
d
reported
to
h
ave
affin
ity
for
N
PBW
1,M
L181
an
d
M
L250,th
e
latter
exh
ibitin
g
im
proved
selec-
tivity
(∼
100
fold)for
N
PBW
1
com
pared
to
M
C
H
1
receptors
[694,
695].
C
om
putation
al
in
sigh
ts
in
to
th
e
bin
din
g
of
an
tagon
ists
to
th
is
receptor
h
ave
also
been
described
[1541].
Fu
rth
er
read
in
g
o
n
N
eu
ro
p
ep
tid
e
W
/n
eu
ro
p
ep
tid
e
B
recep
to
rs
SakuraiT.(2013)
N
PBW
R
1
an
d
N
PBW
R
2:Im
plication
s
in
En
ergy
H
om
eostasis,Pain
,an
d
Em
otion
.
FrontEndocrinol(Lausanne)4
:23
[PM
ID
:23515889]
Sin
gh
G
et
al.
(2006)
N
europeptide
B
an
d
W
:n
eurotran
sm
itters
in
an
em
ergin
g
G
-protein
-coupled
receptor
system
.Br.J.Pharm
acol.148
:1033-41
[PM
ID
:16847439]
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N
europeptide
Y
receptors
G
protein
-coupled
receptors→
N
europeptide
Y
receptors
O
verview
:
N
europeptide
Y
(N
PY
)
receptors
(n
o
m
en
clatu
re
as
ag
reed
b
y
th
e
N
C
-IU
P
H
A
R
Su
b
co
m
m
ittee
o
n
N
eu
ro
p
ep
-
tid
e
Y
R
ecep
to
rs
[1330])
are
activated
by
th
e
en
dogen
ous
peptides
n
europeptide
Y
(N
PY
,
P01303),
n
europeptide
Y-(3-36),
peptide
Y
Y
(PY
Y
,P10082),PY
Y-(3-36)
an
d
pan
creatic
polypeptide
(PPY
,
P01298)
(PP).
Th
e
receptor
origin
ally
iden
tified
as
th
e
Y
3
receptor
h
as
been
iden
tified
as
th
e
C
X
C
R
4
ch
em
okin
e
recepter
(origin
ally
n
am
ed
LESTR
,
[1201]).
Th
e
y6
receptor
is
a
fun
c-
tion
algen
e
product
in
m
ouse,absen
t
in
rat,but
con
tain
s
a
fram
e-
sh
ift
m
utation
in
prim
ates
producin
g
a
trun
cated
n
on
-fun
ction
al
gen
e
[676].
M
an
y
of
th
e
agon
ists
exh
ibit
differin
g
degrees
of
se-
lectivity
depen
den
t
on
th
e
species
exam
in
ed.
For
exam
ple,
th
e
poten
cy
of
PP
is
greater
at
th
e
rat
Y
4
receptor
th
an
at
th
e
h
u-
m
an
receptor
[513].
In
addition
,
m
an
y
agon
ists
lack
selectiv-
ity
for
in
dividual
subtypes,
but
can
exh
ibit
com
parable
poten
cy
again
st
pairs
of
N
PY
receptor
subtypes,
or
h
ave
n
ot
been
exam
-
in
ed
for
activity
at
all
subtypes.
[ 125I]-PY
Y
or
[ 125I]-N
PY
can
be
used
to
label
Y
1 ,
Y
2 ,
Y
5
an
d
y
6
subtypes
n
on
-selectively,
w
h
ile
[ 125I][cPP(1-7),N
PY
(19-23),A
la 31,A
ib
32,G
ln
34]h
PP
m
ay
be
used
to
labelY
5
receptors
preferen
tially
(n
ote
th
atcPP
den
otes
ch
icken
peptide
sequen
ce
an
d
h
PP
is
th
e
h
um
an
sequen
ce).
N
om
enclature
Y
1
receptor
Y
2
receptor
Y
4
receptor
Y
5
receptor
y6
receptor
H
G
N
C
,U
niProt
N
PY1R,P25929
N
PY2R,P49146
N
PY4R,P50391
N
PY5R,Q
15761
N
PY6R,Q
99463
Potency
order
ofendogenous
ligands
neuropeptide
Y
=
peptide
YY
≫
pancreatic
polypeptide
peptide
YY
=
peptide
YY(3-36)
=
neuropeptide
Y
=
neuropeptide
Y(3-36)≫
pancreatic
polypeptide
pancreatic
polypeptide≫
neuropeptide
Y
=
peptide
YY
neuropeptide
Y
>
peptide
YY
>
pancreatic
polypeptide
neuropeptide
Y
=
peptide
YY
>
pancreatic
polypeptide
Endogenous
agonists
neuropeptide
Y
(N
PY,
P01303),peptide
YY
(PYY,
P10082)
PYY-(3-36)
(PYY,P10082)
[619,633],
neuropeptide
Y
(N
PY,P01303),
neuropeptide
Y-(3-36)
(N
PY,P01303),
peptide
YY
(PYY,P10082)
pancreatic
polypeptide
(PPY,P01298)
[98,1217,
1978,2165]
–
–
Agonists
[Leu
31,Pro
34]N
PY
[392],
[Leu
31,Pro
34]PYY
(hum
an),
[Pro
34]N
PY,
[Pro
34]PYY
(hum
an)
–
–
–
–
Selective
agonists
–
–
–
[Ala 31,Aib
32]N
PY
(pig)
[264]
–
Selective
antagonists
BIBO
3304
(pIC
50
9.5)
[2110],BIBP3226
(pK
i
8.1–9.3)
[463,2111]
BIIE0246
(pIC
50
8.5)
[461],JN
J-5207787
(pIC
50
6.9–7.1)
[182]
–
L-152,804
(pK
i 7.6)
[944]
–
Selective
allosteric
m
odulators
–
–
niclosam
ide
(Positive)
[1827]
–
–
Labelled
ligands
[ 3H
]BIBP3226
(Antagonist)
(pK
d
8.7),
[ 125I][Leu
31,Pro
34]N
PY
(Agonist)
[ 125I]PYY-(3-36)
(hum
an)
(Agonist)
[ 125I]PP
(hum
an)
(Agonist)
[ 125I][cPP(1-7),N
PY(19-23),
Ala 31,Aib
32,G
ln
34]hPP
(Agonist)
[481]–
Rat
–
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N
om
enclature
Y
1
receptor
Y
2
receptor
Y
4
receptor
Y
5
receptor
y6
receptor
C
om
m
ents
N
ote
that
Pro
34-containing
N
PY
and
PYY
can
also
bind
Y
4
and
Y
5
receptors,so
strictly
speaking
are
not
selective,but
are
the
’preferred’agonists.
–
–
–
–
C
o
m
m
en
ts:
Th
e
Y
1
agon
ists
in
dicated
are
selective
relative
to
Y
2
receptors.
BIBP3226
is
selective
relative
to
Y
2 ,
Y
4
an
d
Y
5
receptors
[632].
N
PY-(13-36)
is
Y
2
selective
relative
to
Y
1
an
d
Y
5
receptors.
PY
Y-(3-36)is
Y
2
selective
relative
to
Y
1
receptors.N
ote
th
atPro34-con
tain
in
g
N
PY
an
d
PY
Y
can
also
bin
d
Y
4
an
d
Y
5 ,th
us
th
ey
are
selective
on
ly
relative
to
Y
2 .Th
e
y
6
receptor
is
a
pseudogen
e
in
h
um
an
s,
but
is
fun
ction
alin
m
ouse,rabbit
an
d
som
e
oth
er
m
am
m
als.
Fu
rth
er
read
in
g
o
n
N
eu
ro
p
ep
tid
e
Y
recep
to
rs
Bow
ers
M
E
et
al.
(2012)
N
europeptide
regulation
of
fear
an
d
an
xiety:
Im
plication
s
of
ch
ole-
cystokin
in
,
en
dogen
ous
opioids,
an
d
n
europeptide
Y.
Physiol.
Behav.
107
:
699-710
[PM
ID
:22429904]
M
ich
el
M
C
et
al.
(1998)
X
V
I.
In
tern
ation
al
U
n
ion
of
Ph
arm
acology
recom
m
en
dation
s
for
th
e
n
om
en
clature
of
n
europeptide
Y,
peptide
Y
Y
an
d
pan
creatic
polypeptide
receptors.
Pharm
a-
col.Rev.50
:143-150
[PM
ID
:9549761]
Pedragosa-Badia
X
et
al.
(2013)
N
europeptide
Y
receptors:
h
ow
to
get
subtype
selectivity.
Front
Endocrinol(Lausanne)4
:5
[PM
ID
:23382728]
Zh
an
g
L
etal.(2011)
Th
e
n
europeptide
Y
system
:path
oph
ysiologicalan
d
th
erapeutic
im
plication
s
in
obesity
an
d
can
cer.Pharm
acol.T
her.131
:91-113
[PM
ID
:21439311]
N
eurotensin
receptors
G
protein
-coupled
receptors→
N
euroten
sin
receptors
O
verview
:N
euroten
sin
receptors
(n
o
m
en
clatu
re
as
reco
m
m
en
d
ed
b
y
N
C
-IU
P
H
A
R
[557])are
activated
by
th
e
en
dogen
ous
tridecapeptide
n
euroten
sin
(pG
lu-Leu-Tyr-G
lu-A
sn
-Lys-Pro-A
rg-A
rg-Pro-
Tyr-Ile-Leu)derived
from
a
precursor
(N
T
S,30990),w
h
ich
also
gen
erates
n
eurom
edin
N
,an
agon
ist
atth
e
N
TS2
receptor.[ 3H
]n
euroten
sin
(h
um
an
,m
ouse,rat)an
d
[ 125I]n
euroten
sin
(h
um
an
,m
ouse,rat)
m
ay
be
used
to
labelN
TS1
an
d
N
TS2
receptors
at
0.1-0.3
an
d
3-5
n
M
con
cen
tration
s
respectively.
N
om
enclature
N
TS1
receptor
N
TS2
receptor
H
G
N
C
,U
niProt
N
TSR1,P30989
N
TSR2,O
95665
Potency
order
ofendogenous
ligands
neurotensin
(N
TS,P30990)
>
neurom
edin
N
{M
ouse,Rat}
[776]
neurotensin
(N
TS,P30990)
=
neurom
edin
N
{M
ouse,Rat}
[1297]
Selective
agonists
JM
V449
[1822]–
Rat
levocabastine
[1297,1657]
Selective
antagonists
m
eclinertant
(pIC
50
7.5–8.2)
[699]
–
Labelled
ligands
[ 3H
]m
eclinertant
(Antagonist)
(pK
d
8.5)
[1085]–
Rat
–
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database:http://w
w
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C
o
m
m
en
ts:
n
euroten
sin
(N
T
S,
P30990)
appears
to
be
a
low
-
efficacy
agon
istatth
e
N
TS2
receptor[2039],w
h
ile
th
e
N
TS1
recep-
toran
tagon
istm
eclin
ertan
tis
an
agon
istatN
TS2
receptors
[2039].
A
n
addition
alprotein
,provision
ally
term
ed
N
TS3
(also
kn
ow
n
as
N
TR
3,gp95
an
d
sortilin
;EN
SG
00000134243),h
as
been
suggested
to
bin
d
lipoprotein
lipase
an
d
m
ediate
its
degradation
[1460].
It
h
as
been
reported
to
in
teract
w
ith
th
e
N
TS1
receptor
[1273]
an
d
th
e
N
TS2
receptor[260],an
d
h
asbeen
im
plicated
in
h
orm
on
e
traf-
fickin
g
an
d/or
n
euroten
sin
uptake.
A
splice
varian
t
of
th
e
N
TS2
receptor
bearin
g
5
tran
sm
em
bran
e
dom
ain
s
h
as
been
iden
tified
in
m
ouse
[195]an
d
later
in
rat
[1561].
Fu
rth
er
read
in
g
o
n
N
eu
ro
ten
sin
recep
to
rs
Boules
M
et
al.
(2013)
D
iverse
roles
of
n
euroten
sin
agon
ists
in
th
e
cen
tral
n
ervous
system
.
Front
Endocrinol(Lausanne)4
:36
[PM
ID
:23526754]
M
azella
J
et
al.
(2012)
N
euroten
sin
an
d
its
receptors
in
th
e
con
trol
of
glucose
h
om
eostasis.
Front
Endocrinol(Lausanne)3
:143
[PM
ID
:23230428]
M
yers
R
M
etal.(2009)C
an
cer,ch
em
istry,an
d
th
e
cell:m
olecules
th
atin
teractw
ith
th
e
n
euroten
sin
receptors.A
C
S
C
hem
.Biol.4
:503-25
[PM
ID
:19462983]
Tan
gan
elli
S
et
al.
(2012)
R
elevan
ce
of
dopam
in
e
D
(2)/n
euroten
sin
N
TS1
an
d
N
M
D
A
/n
euroten
sin
N
TS1
receptor
in
teraction
in
psych
iatric
an
d
n
eurodegen
erative
disorders.
C
urr.
M
ed.
C
hem
.
19
:304-16
[PM
ID
:22335510]
O
pioid
receptors
G
protein
-coupled
receptors→
O
pioid
receptors
O
verview
:
O
pioid
an
d
opioid-like
receptors
are
activated
by
a
variety
of
en
dogen
ous
peptides
in
cludin
g
[M
et]en
keph
alin
(PEN
K
,
P01210)
(m
et),
[Leu]en
keph
alin
(PEN
K
,
P01210)
(leu),
β-en
dorph
in
(PO
M
C
,
P01189)
(β-en
d),
α
-n
eodyn
orph
in
(PD
Y
N
,
P01213),
dyn
orph
in
A
(PD
Y
N
,
P01213)
(dyn
A
),
dyn
orph
in
B
(PD
Y
N
,
P01213)
(dyn
B),
big
dyn
orph
in
(PD
Y
N
,
P01213)
(Big
dyn
),
n
ociceptin
/orph
an
in
FQ
(PN
O
C
,
Q
13519)
(N
/O
FQ
);
en
dom
orph
in
-1
an
d
en
dom
orph
in
-2
are
also
poten
tial
en
doge-
n
ous
peptides.
Th
e
G
reek
letter
n
om
en
clature
for
th
e
opioid
receptors,µ
,δ
an
d
κ
,is
w
ell
establish
ed,an
d
N
C
-IU
P
H
A
R
con
-
siders
th
is
n
om
en
clature
appropriate,
alon
g
w
ith
th
e
sym
bols
spelled
out
(m
u,
delta,
an
d
kappa),
an
d
th
e
acron
ym
s,
M
O
P,
D
O
P,
an
d
K
O
P.
[390,
441,
557].
Th
e
h
um
an
N
/O
FQ
receptor,
N
O
P,
is
con
sidered
’opioid-related’
rath
er
th
an
opioid
because,
w
h
ile
it
exh
ibits
a
h
igh
degree
of
structural
h
om
ology
w
ith
th
e
con
ven
tion
al
opioid
receptors
[1361],
it
displays
a
distin
ct
ph
ar-
m
acology.
C
urren
tly
th
ere
are
n
um
erous
clin
ically
used
drugs,
such
as
m
orph
in
e
an
d
m
an
y
oth
er
opioid
an
algesics,
as
w
ell
as
an
tagon
ists
such
as
n
aloxon
e,h
ow
ever
on
ly
for
th
e
µ
receptor.
N
om
enclature
δ
receptor
κ
receptor
µ
receptor
N
O
P
receptor
H
G
N
C
,U
niProt
O
PRD
1,P41143
O
PRK1,P41145
O
PRM
1,P35372
O
PRL1,P41146
Principalendogenous
agonists
β-endorphin
(PO
M
C,P01189),[Leu]enkephalin
(PEN
K,P01210),[M
et]enkephalin
(PEN
K,P01210)
big
dynorphin
(PD
YN
,P01213),dynorphin
A
(PD
YN
,P01213)
β-endorphin
(PO
M
C,P01189),
[M
et]enkephalin
(PEN
K,P01210),
[Leu]enkephalin
(PEN
K,P01210)
nociceptin/orphanin
FQ
(PN
O
C,
Q
13519)
[11,153,1507]
Potentialendogenous
agonists
–
–
endom
orphin-1,endom
orphin-2
–
Agonists
D
AD
LE
[1972],etorphine
[1972],
ethylketocyclazocine
[1972]
–
levorphanol[727],
hydrom
orphone
[2094],fentanyl
[1972],buprenorphine
(Partial
agonist)
[1972],m
ethadone
[1595],codeine
[1972],
tapentadol[1992],pethidine
[1595]
–
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w
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N
om
enclature
δ
receptor
κ
receptor
µ
receptor
N
O
P
receptor
Sub/fam
ily-selective
agonists
BU
08028
(Partialagonist)
[979]
BU
08028
[979]
BU
08028
(Partialagonist)
[979]
cebranopadol[1182],BU
08028
(Partialagonist)
[979]
Selective
agonists
U
FP-512
[2033],BW
373U
86
[1115],AD
L5859
[1115],D
PD
PE
[1391,1972],
[D
-Ala 2]deltorphin
II[515],AD
L5747
[1116],
SN
C
80
[268,1620]
U
50488
[313,1545,1813,1972,2046,
2222,2224],enadoline
[848,1447],U
69593
[1089,1972],salvinorin
A
[259,1677]
sufentanil[2041],D
AM
G
O
[726,
1972],loperam
ide
[323],
m
orphine
[653,1972],PL017
[304,1972]
N
/O
FQ
-(1-13)-N
H
2
[153,696,
1304,1507],Ac-RYYRW
K-N
H
2
(Partialagonist)
[464,1304],
SC
H
221510
[2030],Ro64-6198
[898,2108]
Antagonists
naltrexone
(pK
i 8)
[1972],naloxone
(pK
i 7.2)
[1972]
buprenorphine
(pK
i 9.1–10.2)
[1972,2224],
nalm
efene
(pK
i 9.5)
[1972],naltrexone
(pK
i
8.4–9.4)
[1545,1813,1972],naloxone
(pK
i
7.6–8.6)
[1545,1813,1972,2222,2224]
naltrexone
(pK
i 9.1–9.7)
[965,
1972],nalm
efene
(pK
i 9.5)
[1972],nalorphine
(pK
i 8.9)
[1972],naloxone
(pK
i 8.9)[1972],
m
ethylnaltrexone
(pK
i 8.7)
[2094]
–
Sub/fam
ily-selective
antagonists
AT-076
(pK
i 7.7)
[1972,2201]
AT-076
(pK
i 8.9)
[1972,2202]
AT-076
(pK
i 8.8)
[1972,2202]
AT-076
(pK
i 8.8)
[2202]
Selective
antagonists
naltriben
(pK
i 10)
[1841,1972],naltrindole
(pK
i
9.7)
[1594,1972],TIPPψ
(Inverse
agonist)
(pK
i
9)
[1735,1972]
nor-binaltorphim
ine
(pK
i 8.9–11)
[1545,
1593,1813,1972,2222,2224],
5’-guanidinonaltrindole
(pK
i 9.7–9.9)
[924,
1545,1868],JD
Tic
(pK
i 9–9.4)
[1400,1951,
2202]
alvim
opan
(pK
i 9.3)
[1114],
levallorphan
(pK
i 8.8–9.3)
[1250],
C
TAP
(pK
i 8.6)
[304,1972]
U
FP-101
(pK
i 10.2)
[269],
LY2940094
(pK
i 10)
[1971],
com
pound
24
(pK
i 9.6)
[549],
SB
612111
(pK
i 9.2–9.5)
[1856,
2200],J-113397
(pIC
50
8.3)
[962]
Allosteric
m
odulators
–
–
BM
S-986123
(N
eutral)
(pK
B
6)
[247],BM
S-986121
(Positive)
(pK
B
5.7)
[247],BM
S-986124
(N
eutral)
(pK
B
5.7)
[247],
BM
S-986122
(Positive)
(pK
B
5.3)
[247]
–
Labelled
ligands
[ 3H
]naltrindole
(Antagonist)
(pK
d
10.4)
[2161]–
Rat,[ 3H
][D
-Ala2]deltorphin
I(Selective
Agonist)
[1865],[ 3H
]diprenorphine
(Agonist)
[52,1972],
[ 3H
]D
PD
PE
(Agonist)
[26],[ 3H
]deltorphin
II
(Agonist)[261],[ 3H
]naltriben
(Antagonist)[1154]
[ 3H
]diprenorphine
(Antagonist)
(pK
d
9.1)
[52,1813],[ 3H
]U
69593
(Agonist)
[1089,
1545,1813],[ 3H
]enadoline
(Agonist)
[1815]
[ 3H
]diprenorphine
(Antagonist)
(pK
d
10.1)
[1638]–
M
ouse,
[ 3H
]D
AM
G
O
(Agonist)
[1638]–
Rat,[ 3H
]PL017
(Agonist)
[751]–
Rat
[ 3H
]N
/O
FQ
(Agonist)
[464,
1360]
C
o
m
m
en
ts:Th
ree
n
aloxon
e-sen
sitive
opioid
receptorgen
esh
ave
been
iden
tified
in
h
um
an
s,
an
d
w
h
ile
th
e
µ
-receptor
in
particu-
lar
m
ay
be
subject
to
exten
sive
altern
ative
splicin
g
[1535],
th
ese
putative
isoform
s
h
ave
n
ot
been
correlated
w
ith
an
y
of
th
e
sub-
types
of
receptor
proposed
in
years
past.
O
pioid
receptors
m
ay
h
eterodim
erize
w
ith
each
oth
erorw
ith
oth
er7TM
receptors[926],
an
d
give
rise
to
com
plexes
w
ith
a
un
ique
ph
arm
acology,h
ow
ever,
eviden
ce
forsuch
h
eterodim
ers
in
n
ative
cells
is
equivocalan
d
th
e
con
sequen
ces
of
th
is
h
eterodim
erization
for
sign
allin
g
rem
ain
s
largely
un
kn
ow
n
.
For
µ
-opioid
receptors
at
least,
dim
erization
does
n
ot
seem
to
be
required
for
sign
allin
g
[1078].A
distin
ct
m
et-
en
keph
alin
receptor
lackin
g
structural
resem
blan
ce
to
th
e
opioid
receptors
listed
h
as
been
iden
tified
(O
G
FR,9N
ZT2)an
d
term
ed
an
opioid
grow
th
factor
receptor
[2198].
En
dom
orph
in
-1
an
d
en
dom
orph
in
-2
h
ave
been
iden
tified
as
h
igh
ly
selective,
putative
en
dogen
ous
agon
ists
for
th
e
µ
-opioid
receptor.
A
t
presen
t,h
ow
ever,th
e
m
ech
an
ism
s
for
en
dom
orph
in
syn
th
esis
in
vivo
h
ave
n
ot
been
establish
ed,
an
d
th
ere
is
n
o
gen
e
iden
tified
th
at
en
codes
for
eith
er.
Th
us,
th
e
status
of
th
ese
pep-
tides
as
en
dogen
ous
ligan
ds
rem
ain
s
un
proven
.
Tw
o
areas
of
in
creasin
g
im
portan
ce
in
defin
in
g
opioid
recep-
tor
fun
ction
are
th
e
presen
ce
of
fun
ction
ally
relevan
t
sin
gle
n
u-
cleotide
polym
orph
ism
s
in
h
um
an
µ
-receptors
[1490]
an
d
th
e
iden
tification
of
biased
sign
allin
g
by
opioid
receptor
ligan
ds,
in
particular,
com
poun
ds
previously
ch
aracterized
as
an
tagon
ists
[236].
Path
w
ay
bias
for
agon
ists
m
akes
gen
eralran
k
orders
of
po-
ten
cy
an
d
efficacy
som
ew
h
at
obsolete,
so
th
ese
do
n
ot
appear
in
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database:http://w
w
w.guidetopharm
acology.org/index.jsp
O
pioid
receptors
S96
FullC
ontents
ofC
onciseG
uide:http://onlinelibrary.w
iley.com
/doi/10.1111/bph.13878/full
S.P.H.Alexanderetal.The
Concise
Guide
to
PHARM
ACOLOGY
2017/18:G
protein-coupled
receptors.British
JournalofPharm
acology
(2017)174,S17–S129
th
e
table.A
s
ever,th
e
m
ech
an
ism
s
un
derlyin
g
th
e
acute
an
d
lon
g
term
regulation
of
opiod
receptor
fun
ction
are
th
e
subject
of
in
-
ten
se
in
vestigation
an
d
debate.
Th
e
rich
n
ess
ofopioid
receptor
ph
arm
acology
h
as
been
en
h
an
ced
w
ith
th
e
recen
t
discovery
of
allosteric
m
odulators
of
µ
an
d
δ
re-
ceptors,
n
otably
th
e
positive
allosteric
m
odulators
an
d
silen
t
al-
losteric
"an
tagon
ists"
outlin
ed
in
[247,
248].
N
egative
allosteric
m
odulation
of
opioid
receptors
h
as
been
previously
suggested
[953],w
h
eth
er
allcom
poun
ds
are
actin
g
at
a
sim
ilar
site
rem
ain
s
to
be
establish
ed.
Fu
rth
er
read
in
g
o
n
O
p
io
id
recep
to
rs
Butelm
an
ER
et
al.
(2012)
κ
-opioid
receptor/dyn
orph
in
system
:
gen
etic
an
d
ph
arm
acoth
erapeutic
im
plication
s
for
addiction
.Trends
N
eurosci.35
:587-96
[PM
ID
:22709632]
C
ox
BM
et
al.
(2015)
C
h
allen
ges
for
opioid
receptor
n
om
en
clature:
IU
PH
A
R
R
eview
9.
Br.
J.Phar-
m
acol.172
:317-23
[PM
ID
:24528283]
Pradh
an
A
A
et
al.
(2011)
Th
e
delta
opioid
receptor:
an
evolvin
g
target
for
th
e
treatm
en
t
of
brain
disorders.Trends
Pharm
acol.Sci.32
:581-90
[PM
ID
:21925742]
W
illiam
s
JT
etal.(2013)
R
egulation
of
µ
-opioid
receptors:desen
sitization
,ph
osph
orylation
,in
ter-
n
alization
,an
d
toleran
ce.
Pharm
acol.Rev.65
:223-54
[PM
ID
:23321159]
O
rexin
receptors
G
protein
-coupled
receptors→
O
rexin
receptors
O
verview
:O
rexin
receptors
(n
o
m
en
clatu
re
as
ag
reed
b
y
th
e
N
C
-IU
P
H
A
R
Su
b
co
m
m
ittee
o
n
O
rex
in
recep
to
rs
[557])
are
activated
by
th
e
en
dogen
ous
polypeptides
orexin
-A
(H
C
RT
,O
43612)
an
d
orexin
-B
(H
C
RT
,O
43612)
(also
kn
ow
n
as
h
ypocretin
-1
an
d
-2;33
an
d
28
aa)
derived
from
a
com
m
on
precursor,preproorexin
or
orexin
precursor,by
proteolytic
cleavage
[1703].
N
om
enclature
O
X
1
receptor
O
X
2
receptor
H
G
N
C
,U
niProt
H
CRTR1,O
43613
H
CRTR2,O
43614
Potency
order
ofendogenous
ligands
orexin-A
(H
CRT,O
43612)
>
orexin-B
(H
CRT,O
43612)
orexin-A
(H
CRT,O
43612)
=
orexin-B
(H
CRT,O
43612)
Selective
agonists
–
[Ala 11,D
-Leu
15]orexin-B
[66,1612]
Selective
antagonists
suvorexant
(pK
i 9.3)
[391],SB-649868
(pK
i 9.1)
[442],SB-674042
(pK
i
8.7–9.1)
[1098,1253,1255],filorexant
(pK
i 8.6)
[2124],alm
orexant
(pIC
50
7.9)
[221],SB-408124
(pK
i 7.2–7.6)
[1098,1253],SB-334867
(pK
i 7.4–7.5)
[1253,1591]
filorexant
(pK
i 9.5)
[2124],suvorexant
(pK
i 9.5)
[391],EM
PA
(pK
i 9)
[1252],
SB-649868
(pK
i 8.9)
[442],JN
J-10397049
(pK
i 8–8.6)
[1300],alm
orexant
(pIC
50
8.1)
[221],TC
S-O
X
2-29
(pK
i 7.4)
[798]
Labelled
ligands
–
[ 3H
]-alm
orexant
(Selective
Antagonist)
(pK
d
8.9–9.8)
[1253,1255],[ 3H
]C
p-1
(Selective
Antagonist)
(pK
d
9.2–9.4)
[1253],[ 3H
]EM
PA
(Selective
Antagonist)
(pK
d
8.6–9)
[1252,1255],[ 125I]-orexin-A
(Agonist)
[1066,1611,1703]
C
o
m
m
en
ts:
Th
e
prim
ary
couplin
g
of
orexin
receptors
to
G
q/11
protein
s
is
rath
er
speculative
an
d
based
on
th
e
stron
g
activation
of
ph
osph
olipase
C
,
th
ough
recen
t
studies
in
recom
bin
an
t
C
H
O
cells
also
stress
th
e
im
portan
ce
ofG
q/11
[1065].C
ouplin
g
ofboth
receptors
to
G
i/o
an
d
G
s
h
as
also
been
reported
[951,1068,1146,
1629]
for
m
ost
cellular
respon
ses
observed,
th
e
G
protein
path
-
w
ay
is
un
kn
ow
n
.
Th
e
poten
cy
order
of
en
dogen
ous
ligan
ds
m
ay
depen
d
on
th
e
cellular
sign
al
tran
sduction
m
ach
in
ery.
M
ost
of
th
e
O
X
2
receptor
selective
an
tagon
ists
listed
are
w
eakly
selective
(≤
10-fold),orselectivity
m
ay
be
lessth
an
100-fold
orn
otun
equiv-
ocally
determ
in
ed.[A
la 11,D
-Leu
15]orexin
-B
m
ay
sh
ow
poor
O
X
2
receptor
selectivity
[1612].
O
rexin
receptors
h
ave
been
reported
to
be
able
to
form
com
-
plexes
w
ith
each
oth
er
an
d
som
e
oth
er
G
PC
R
s
as
w
ell
as
C
R
F
receptors
[1067,1426],w
h
ich
m
igh
t
affect
th
e
sign
alin
g
an
d
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ph
arm
acology.R
ecen
tly
a
prom
isin
g
syn
th
etic
orexin
receptorlig-
an
d
(com
poun
d
26)h
as
been
reported
butn
otth
orough
ly
ch
arac-
terized
[1412].
Loss-of-fun
ction
m
utation
s
in
th
e
gen
e
en
codin
g
th
e
O
X
2
receptor
un
derlie
can
in
e
h
ereditary
n
arcolepsy
[1177].
A
n
tagon
ists
of
th
e
orexin
receptors
are
th
e
focus
of
m
ajor
drug
discovery
effortforth
eirpoten
tialto
treatin
som
n
ia
an
d
oth
erdis-
orders
ofw
akefuln
ess
[1668],w
h
ile
agon
ists
w
ould
likely
be
useful
in
h
um
an
n
arcolepsy.
Fu
rth
er
read
in
g
o
n
O
rex
in
recep
to
rs
Baim
el
C
et
al.
(2015)
O
rexin
/h
ypocretin
role
in
rew
ard:
im
plication
s
for
opioid
an
d
oth
er
addic-
tion
s.Br.J.Pharm
acol.172
:334-48
[PM
ID
:24641197]
K
ukkon
en
JP.(2013)Ph
ysiology
ofth
e
orexin
ergic/h
ypocretin
ergic
system
:a
revisit
in
2012.A
m
.J.
Physiol.,C
ellPhysiol.304
:C
2-32
[PM
ID
:23034387]
LiSB
et
al.
(2016)
H
ypocretin
s,N
euralSystem
s,Ph
ysiology,an
d
Psych
iatric
D
isorders.
C
urr
Psychi-
atry
Rep
18
:7
[PM
ID
:26733323]
M
ah
ler
SV
et
al.
(2014)
M
otivation
alactivation
:
a
un
ifyin
g
h
ypoth
esis
of
orexin
/h
ypocretin
fun
c-
tion
.N
at.N
eurosci.17
:1298-303
[PM
ID
:25254979]
O
xoglutarate
receptor
G
protein
-coupled
receptors→
O
xoglutarate
receptor
O
verview
:N
o
m
en
clatu
re
as
reco
m
m
en
d
ed
b
y
N
C
-IU
P
H
A
R
[414].
N
om
enclature
oxoglutarate
receptor
H
G
N
C
,U
niProt
O
XG
R1,Q
96P68
Endogenous
agonists
α
-ketoglutaric
acid
[762,1854]
P2Y
receptors
G
protein
-coupled
receptors→
P2Y
receptors
O
verview
:
P2Y
receptors
(n
o
m
en
clatu
re
as
ag
reed
b
y
th
e
N
C
-IU
P
H
A
R
Su
b
co
m
m
ittee
o
n
P
2Y
R
ecep
to
rs
[1,
2])
are
activated
by
th
e
en
dogen
ous
ligan
ds
A
TP,
A
D
P,
uridin
e
triph
osph
ate,uridin
e
diph
osph
ate
an
d
U
D
P-glucose.
Th
e
relation
sh
ip
ofm
an
y
ofth
e
clon
ed
receptors
to
en
dogen
ously
ex-
pressed
receptors
is
n
ot
yet
establish
ed
an
d
so
it
m
igh
t
be
appro-
priate
to
use
w
ordin
g
such
as
’uridin
e
triph
osph
ate-preferrin
g
(or
A
TP-,
etc.)
P2Y
receptor’
or
’P2Y
1 -like’,
etc.,
un
til
furth
er,
as
yet
un
defin
ed,
corroborative
criteria
can
be
applied
[251,
514,
878,
2044,2089].
C
lin
ically
used
drugs
actin
g
on
th
ese
receptors
in
clude
th
e
din
u-
cleoside
polyph
osph
ate
diquafosol,
agon
ist
of
th
e
P2Y
2
receptor
subtype,approved
in
Japan
forth
e
m
an
agem
en
tofdry
eye
disease
[1101],
an
d
th
e
P2Y
12
receptor
an
tagon
ists
prasugrel,
ticagrelor
an
d
can
grelor,allapproved
as
an
tiplatelet
drugs
[273,1602].
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N
om
enclature
P2Y
1
receptor
P2Y
2
receptor
P2Y
4
receptor
P2Y
6
receptor
H
G
N
C
,U
niProt
P2RY1,P47900
P2RY2,P41231
P2RY4,P51582
P2RY6,Q
15077
Potency
order
ofendogenous
ligands
AD
P>
ATP
uridine
triphosphate
>
ATP
[1112]
uridine
triphosphate>
ATP
(at
rat
recom
binant
receptors,U
TP
=
ATP)
uridine
diphosphate≫
uridine
triphosphate
>
AD
P
Endogenous
agonists
–
uridine
triphosphate
[989,1112]
–
–
Agonists
AD
PβS
[1921],2M
eSAD
P
[1729,2054]
–
–
–
Sub/fam
ily-selective
agonists
–
diquafosol[1554],denufosol[1113,
1554,2181],U
TPγS
[1112]
diquafosol[240],denufosol
[2181],U
TPγS
[1113]
–
Selective
agonists
M
RS2365
[329],2-C
l-AD
P(α
-BH
3 )
[76]
M
RS2698
[874],2-thioU
TP
[498],
PSB1114
(EC
50
value
determ
ined
using
an
IP
3
functionalassay)
[498,499,873]
M
RS4062
[1276],M
RS2927
[1276],(N
)m
ethanocarba-U
TP
[989]
Rp-5-O
M
e-U
D
Pα
B
[644,702],
M
RS2957
[1275],M
RS2693
[146]
Antagonists
suram
in
(pK
i 5.3)
[2054],PPAD
S
(pK
i 5.2)
[2054]
–
ATP
(pK
d
6.2)
[970]
–
Sub/fam
ily-selective
antagonists
–
reactive
blue-2
(pIC
50
6)
[892],suram
in
(pIC
50
4.3)
[892,1729]
PPAD
S
(pEC
50
2–5)
[881],
reactive
blue-2
(pIC
50
4.7)
[171]
–
Rat
reactive
blue-2
(pK
B
6)
[2045],
PPAD
S
(pK
B
4)
[2045],suram
in
(pK
B
4)
[2045]
Selective
antagonists
M
RS2500
(pK
i 8.8–9.1)
[286,988],
M
RS2279
(pK
i 7.9)
[2054],M
RS2179
(pK
i
7–7.1)
[203,2054]
AR-C
118925X
X
(pIC
50 ∼
6)
[968],
AR-C
126313
(pEC
50
6)
[874],PSB-416
(pIC
50
4.7)
[792]
ATP
(pK
d
6.2)
[970]
M
RS2578
(pIC
50
7.4)
[1257],
M
RS2567
(pIC
50
6.9)
[1257]
Allosteric
m
odulators
2,2’-pyridylisatogen
tosylate
(N
egative)
(pIC
50
7.8)
[601]
–
–
–
Selective
allosteric
m
odulators
BM
S
com
pound
16
(N
egative)
(pK
i 6.9)
[2206]
–
–
–
Labelled
ligands
[ 3H
]M
RS2279
(Antagonist)
(pK
d
8.1)
[2054],
[ 3H
]2M
eSAD
P
(Agonist)
[1921],[ 35S]AD
PβS
(Agonist)
–
–
M
RS4162
(Selective
Antagonist)
(pEC
50
7.6)
[897]
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N
om
enclature
P2Y
11
receptor
P2Y
12
receptor
P2Y
13
receptor
P2Y
14
receptor
H
G
N
C
,U
niProt
P2RY11,Q
96G
91
P2RY12,Q
9H
244
P2RY13,Q
9BPV8
P2RY14,Q
15391
Potency
order
ofendogenous
ligands
ATP
AD
P
[775]
AD
P≫
ATP
uridine
diphosphate
[281]
Sub/fam
ily-selective
agonists
–
2M
eSAD
P
[775],AD
PβS
[1921]
2M
eSAD
P
[1271],2M
eSATP
[1271],AD
PβS
[1271]
–
Selective
agonists
AR-C
67085
[93,372],N
F546
[1317],ATPγS
[372]
–
–
α
.β-m
ethylene-2-thio-U
D
P
[407],M
RS2905
[879],
2-thio-U
D
P
[407]
Antagonists
–
PSB-0739
(pK
i 7.6)
[97]
–
–
Sub/fam
ily-selective
antagonists
suram
in
(pIC
50
4.8–6)
[372],
reactive
blue-2
(pIC
50
5)
[372]
cangrelor
(pIC
50
9.4)
[882],Ap
4 A
(pIC
50
6)
[1271],2M
eSAM
P
(pIC
50
5.4)
[1921]
cangrelor
(pIC
50
8.3)
[1271],Ap
4 A
(pIC
50
6.7)
[1271],2M
eSAM
P
(pIC
50
5.6)
[1271]
–
Selective
antagonists
N
F157
(pK
i 7.3)
[1999],
N
F340
(pIC
50
6.4–7.1)
[1317]
AZD
1283
(pK
i 8)
[79,2207],ARL66096
(pIC
50
7.9)
[846,847],ticagrelor
(pK
i
7.8)
[2203]
M
RS2603
(pIC
50
6.2)
[996],M
RS2211
(pIC
50
6)
[996]
PPTN
(pK
i 10.1)
[102]
Labelled
ligands
–
[ 3H
]2M
eSAD
P
(Agonist)
[1921],
[ 3H
]PSB-0413
(Antagonist)
(pK
d
8.3–8.5)
[497,1497]
[ 33P]2M
eSAD
P
(Agonist)
[1271]
M
RS4174
(Selective
Antagonist)
(pK
i 10.1)
[1006],
M
RS4183
(Selective
Agonist)
[1005]
C
o
m
m
en
ts:
A
series
of
4-alkyloxyim
in
o
derivatives
of
uridin
e-
5’-triph
osph
ate
w
h
ich
could
be
usefulforderivatization
asfluores-
cen
tP2Y
2/4/6
receptorprobes
h
as
been
recen
tly
syn
th
esized
[897].
Sin
gle
n
ucleotide
polym
orph
ism
s
of
th
e
P2Y
R
1
gen
e
are
associ-
ated
w
ith
differen
tplateletreactivity
to
A
D
P
A
D
P
[784].Th
ree
fre-
quen
t
n
on
syn
on
ym
ous
P2Y
2
receptor
polym
orph
ism
s
h
ave
been
iden
tified,
on
e
of
w
h
ich
w
as
sign
ifican
tly
m
ore
com
m
on
in
cys-
tic
fibrosis
patien
ts.
Th
is
polym
orph
ism
is
lin
ked
to
in
creases
in
C
a 2+
in
flux
in
tran
sfected
cells,
an
d
m
igh
t
th
erefore
play
a
role
in
disease
developm
en
t[263].A
lth
ough
uridin
e
triph
osph
ate
(U
TP)
w
as
also
sh
ow
n
to
be
a
biased
agon
ist
at
P2Y
11 ,th
is
is
still
un
der
debate
[1388,
2104].
A
group
of
sin
gle
n
ucleotide
poly-
m
orph
ism
s
in
th
e
P2Y
12
gen
e,
form
in
g
th
e
so
called
P2Y
12
H
2
h
aplotype,h
as
been
associated
w
ith
in
creased
plateletrespon
sive-
n
ess
to
A
D
P,in
creased
risk
of
periph
eralarterialdisease
an
d
w
ith
coron
ary
artery
disease
[291].
Th
e
platelet-type
bleedin
g
disorder
due
to
P2Y
12
receptor
defects
is
an
autosom
alrecessive
con
dition
ch
aracterized
by
m
ild
to
m
oderate
m
ucocutan
eous
bleedin
g
an
d
excessive
bleedin
g
aftersurgery
ortraum
a.Th
e
defectis
due
to
th
e
in
ability
of
A
D
P
to
in
duce
platelet
aggregation
[287].
Th
e
P2Y
13
receptor
M
et-158-Th
r
polym
orph
ism
,w
h
ich
is
in
lin
kage
disequi-
librium
w
ith
th
e
P2Y
12
locus,
is
n
ot
associated
w
ith
acute
m
y-
ocardial
in
farction
,
diabetes
m
ellitus
or
related
risk
factors
[44].
Th
e
P2Y
14
receptor
w
as
previously
con
sidered
to
exclusively
bin
d
sugar
n
ucleotides
such
as
U
D
P-glucose
an
d
U
D
P-galactose
[299].
H
ow
ever,m
ore
recen
t
eviden
ce
w
ith
severalcelllin
es
h
as
dem
on
-
strated
th
aturidin
e
diph
osph
ate
(U
D
P)is
5-fold
m
ore
poten
tth
an
U
D
P-glucose
[281].U
D
P
w
as
also
sh
ow
n
to
com
petitively
an
tago-
n
ise
th
e
U
D
P-glucose
respon
se
at
th
e
h
um
an
recom
bin
an
t
P2Y
14
receptor
[578].
Fu
rth
er
read
in
g
o
n
P
2Y
recep
to
rs
A
bbracch
io
M
P
et
al.
(2006)
In
tern
ation
al
U
n
ion
of
Ph
arm
acology
LV
III:
update
on
th
e
P2Y
G
protein
-coupled
n
ucleotide
receptors:
from
m
olecular
m
ech
an
ism
s
an
d
path
oph
ysiology
to
th
erapy.Pharm
acol.Rev.58
:281-341
[PM
ID
:16968944]
Jacobson
K
A
etal.(2015)N
ucleotides
A
ctin
g
atP2Y
R
eceptors:C
on
n
ectin
g
Structure
an
d
Fun
ction
.
M
ol.Pharm
acol.88
:220-30
[PM
ID
:25837834]
von
K
ügelgen
I
etal.(2016)
Ph
arm
acology
an
d
structure
of
P2Y
receptors.
N
europharm
acology
104
:
50-61
[PM
ID
:26519900]
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Parathyroid
horm
one
receptors
G
protein
-coupled
receptors→
Parath
yroid
h
orm
on
e
receptors
O
verview
:
Th
e
parath
yroid
h
orm
on
e
receptors
(n
o
m
en
clatu
re
as
ag
reed
b
y
th
e
N
C
-IU
P
H
A
R
Su
b
co
m
m
ittee
o
n
P
arath
yro
id
H
o
rm
o
n
e
R
ecep
to
rs
[606])
are
fam
ily
B
G
protein
-coupled
receptors.
Th
e
parath
yroid
h
orm
on
e
(PTH
)/parath
yroid
h
orm
on
e-related
peptide
(PTH
rP)
receptor
(PTH
1
receptor)
is
activated
by
precursor-derived
peptides:
PTH
(PT
H
,P01270)
(84
am
in
o
acids),an
d
PTH
rP
(PT
H
LH
,P12272)
(141
am
in
o-acids)
an
d
related
peptides
(PTH
-(1-34),PTH
rP-(1-36)
(PT
H
LH
,P12272)).
Th
e
parath
yroid
h
orm
on
e
2
receptor
(PTH
2
receptor)
is
activated
by
th
e
precursor-derived
peptide
TIP39
(PT
H
2,Q
96A
98)
(39
am
in
o
acids).[ 125I]PTH
m
ay
be
used
to
labelboth
PTH
1
an
d
PTH
2
receptors.
N
om
enclature
PTH
1
receptor
PTH
2
receptor
H
G
N
C
,U
niProt
PTH
1R,Q
03431
PTH
2R,P49190
Potency
order
ofendogenous
ligands
PTH
(PTH
,P01270)
=
PTH
rP
(PTH
LH
,P12272)
TIP39
(PTH
2,Q
96A98),PTH
(PTH
,P01270)≫
PTH
rP
(PTH
LH
,P12272)
Agonists
teriparatide
[604]
TIP39
(PTH
2,Q
96A98)
[661,804]
Selective
agonists
PTH
rP-(1-34)
(hum
an)
[605]–
Rat
–
C
o
m
m
en
ts:Th
e
parath
yroid
h
orm
on
e
type
1
receptor
(PTH
R
)
is
th
e
can
on
icalG
PC
R
for
PTH
an
d
PTH
rP.It
is
coupled
to
G
s
an
d
G
q
an
d
regulates
th
e
developm
en
t
ofbon
e,h
eart,m
am
m
ary
glan
ds
an
d
oth
er
tissues
in
respon
se
to
PTH
rP,an
d
blood
con
cen
tration
s
of
calcium
an
d
ph
osph
ate
ion
s,as
w
ellas
vitam
in
D
,in
respon
se
to
PTH
.A
n
oth
er
im
portan
t
action
of
th
e
PTH
/PTH
R
system
is
to
stim
ulate
bon
e
form
ation
w
h
en
th
e
h
orm
on
e
is
in
term
itten
tly
adm
in
istrated
(daily
in
jection
).A
lth
ough
PTH
(PT
H
,P01270)is
an
agon
istath
um
an
PTH
2
receptors,itfails
to
activate
th
e
roden
torth
ologues.
TIP39
(PT
H
2,Q
96A
98)
is
a
w
eak
an
tagon
ist
at
PTH
1
receptors
[925].
Fu
rth
er
read
in
g
o
n
P
arath
yro
id
h
o
rm
o
n
e
recep
to
rs
C
h
eloh
a
RW
etal.(2015)PTH
receptor-1
sign
allin
g-m
ech
an
istic
in
sigh
ts
an
d
th
erapeutic
prospects.
N
atRev
Endocrinol[PM
ID
:26303600]
G
ardella
TJ
et
al.
(2015)
In
tern
ation
al
U
n
ion
of
Basic
an
d
C
lin
ical
Ph
arm
acology.
X
C
III.
Th
e
Parath
yroid
H
orm
on
e
R
eceptors-Fam
ily
B
G
Protein
-C
oupled
R
eceptors.
Pharm
acol.
Rev.
67
:
310-37
[PM
ID
:25713287]
V
ilardaga
JP
et
al.
(2014)
En
dosom
algen
eration
of
cA
M
P
in
G
PC
R
sign
alin
g.
N
at.
C
hem
.
Biol.
10
:
700-6
[PM
ID
:25271346]
Platelet-activating
factor
receptor
G
protein
-coupled
receptors→
Platelet-activatin
g
factor
receptor
O
verview
:Platelet-activatin
g
factor
(PA
F,1-O
-alkyl-2-acetyl-sn
-glycero-3-ph
osph
och
olin
e)
is
an
eth
er
ph
osph
olipid
m
ediator
associated
w
ith
platelet
coagulation
,but
also
subserves
in
flam
m
atory
roles.
Th
e
PA
F
receptor
(p
ro
visio
n
al
n
o
m
en
clatu
re
reco
m
m
en
d
ed
b
y
N
C
-IU
P
H
A
R
[557])
is
activated
by
PA
F
an
d
oth
er
suggested
en
dogen
ous
ligan
ds
are
oxidized
ph
osph
atidylch
olin
e
[1265]
an
d
lysoph
osph
atidylch
olin
e
[1492].It
m
ay
also
be
activated
by
bacteriallipopolysacch
aride
[1417].
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N
om
enclature
PAF
receptor
H
G
N
C
,U
niProt
PTAFR,P25105
Selective
agonists
m
ethylcarbam
ylPAF
Selective
antagonists
foropafant
(pK
i 10.3)
[774],ABT-491
(pK
i 9.2)
[30],C
V-6209
(pIC
50
8.1–8.3)
[652,1416],L659989
(pK
i 7.8)
[851],apafant
(pK
i 5.2–7.5)
[1529,1904]
Labelled
ligands
[ 3H
]PAF
(Agonist)
[585,1416]
C
o
m
m
en
ts:N
ote
th
at
a
previously
recom
m
en
ded
radioligan
d
([ 3H
]apafan
t;K
d
44.6
n
M
)
is
curren
tly
un
available.
Fu
rth
er
read
in
g
o
n
P
latelet-activatin
g
facto
r
recep
to
r
Foord
SM
etal.(2005)In
tern
ation
alU
n
ion
ofPh
arm
acology.X
LV
I.G
protein
-coupled
receptor
list.
Pharm
acolRev
57
:279-288
[PM
ID
:15914470]
Ish
iiS
etal.(2000)Platelet-activatin
g
factor
(PA
F)receptor
an
d
gen
etically
en
gin
eered
PA
F
receptor
m
utan
t
m
ice.Prog.Lipid
Res.39
:41-82
[PM
ID
:10729607]
Prescott
SM
et
al.
(2000)
Platelet-activatin
g
factor
an
d
related
lipid
m
ediators.
A
nnu.
Rev.
Biochem
.
69
:419-45
[PM
ID
:10966465]
Prokineticin
receptors
G
protein
-coupled
receptors→
Prokin
eticin
receptors
O
verview
:
Prokin
eticin
receptors,
PK
R
1
an
d
PK
R
2
(p
ro
vi-
sio
n
al
n
o
m
en
clatu
re
as
reco
m
m
en
d
ed
b
y
N
C
-IU
P
H
A
R
[557])
respon
d
to
th
e
cystein
e-rich
81-86
am
in
o-acid
peptides
prokin
eticin
-1
(PRO
K
1,Q
9H
C
23)(also
kn
ow
n
asen
docrin
e
glan
d-
derived
vascular
en
doth
elial
grow
th
factor,
m
am
bakin
e)
an
d
prokin
eticin
-2
(PRO
K
2,
Q
9H
C
23)
(protein
Bv8
h
om
ologue).
A
n
orth
ologue
of
PR
O
K
1
from
black
m
am
ba
(D
endroaspis
polylepis)
ven
om
,m
am
ba
in
testin
altoxin
1
(M
IT1,[1749])is
a
poten
t,n
on
-
selective
agon
ist
at
prokin
eticin
receptors
[1279],
w
h
ile
Bv8,
an
orth
ologue
of
PR
O
K
2
from
am
ph
ibian
s
(Bom
bina
sp.,
[1357]),
is
equipoten
t
at
recom
bin
an
t
PK
R
1
an
d
PK
R
2
[1435],
an
d
h
as
h
igh
poten
cy
in
m
acroph
age
ch
em
otaxisassays,w
h
ich
are
lostin
PK
R
1 -
n
ullm
ice.
N
om
enclature
PKR
1
PKR
2
H
G
N
C
,U
niProt
PRO
KR1,Q
8TC
W
9
PRO
KR2,Q
8N
FJ6
Potency
order
ofendogenous
ligands
prokineticin-2
(PRO
K2,Q
9H
C
23)
>
prokineticin-1
(PRO
K1,Q
9H
C
23)
>
prokineticin-2β
(PRO
K2)
[1175,1279,1843]
prokineticin-2
(PRO
K2,Q
9H
C
23)
>
prokineticin-1
(PRO
K1,Q
9H
C
23)
>
prokineticin-2β
(PRO
K2)
[1175,1279,1843]
Endogenous
agonists
prokineticin-2
(PRO
K2,Q
9H
C
23)
[316,1279],prokineticin-1
(PRO
K1,Q
9H
C
23)
[316,1279],prokineticin-2β
(PRO
K2)
[316]
prokineticin-2
(PRO
K2,Q
9H
C
23)
[316,1279],prokineticin-1
(PRO
K1,Q
9H
C
23)
[316,1279],prokineticin-2β
(PRO
K2)
[316]
Agonists
M
IT1
[1279]
M
IT1
[1279]
Searchable
database:http://w
w
w.guidetopharm
acology.org/index.jsp
Prokineticin
receptors
S102
FullC
ontents
ofC
onciseG
uide:http://onlinelibrary.w
iley.com
/doi/10.1111/bph.13878/full
S.P.H.Alexanderetal.The
Concise
Guide
to
PHARM
ACOLOGY
2017/18:G
protein-coupled
receptors.British
JournalofPharm
acology
(2017)174,S17–S129
(continued)
N
om
enclature
PKR
1
PKR
2
Selective
agonists
IS20
[612],IS1
[612]
–
Labelled
ligands
[ 125I]BH
-M
IT1
(Agonist)
[1279]
[ 125I]BH
-M
IT1
(Agonist)
[1279]
C
o
m
m
en
ts:
G
en
etic
m
utation
s
in
PRO
K
R1
are
associated
w
ith
H
irsch
sprun
g’s
disease
[1688],
w
h
ile
gen
etic
m
utation
s
in
PRO
K
R2
are
associated
w
ith
h
ypogon
adotropic
h
ypogon
adism
w
ith
an
osm
ia
[455],h
ypopituitarism
w
ith
pituitary
stalk
in
terruption
[1649]an
d
H
irsch
sprun
g’s
disease
[1688].
Fu
rth
er
read
in
g
o
n
P
ro
k
in
eticin
recep
to
rs
Boulberdaa
M
et
al.
(2011)
Prokin
eticin
receptor
1
(PK
R
1)
sign
allin
g
in
cardiovascular
an
d
kidn
ey
fun
ction
s.
C
ardiovasc.Res.92
:191-8
[PM
ID
:21856786]
N
egriL
et
al.
(2012)
Bv8/PK
2
an
d
prokin
eticin
receptors:
a
druggable
pron
ociceptive
system
.
C
urr
O
pin
Pharm
acol12
:62-6
[PM
ID
:22136937]
N
egri
L
et
al.
(2007)
Bv8/Prokin
eticin
protein
s
an
d
th
eir
receptors.
Life
Sci.
81
:
1103-16
[PM
ID
:17881008]
N
gan
ES
et
al.
(2008)
Prokin
eticin
-sign
alin
g
path
w
ay.
Int.
J.
Biochem
.
C
ell
Biol.
40
:
1679-84
[PM
ID
:18440852]
Prolactin-releasing
peptide
receptor
G
protein
-coupled
receptors→
Prolactin
-releasin
g
peptide
receptor
O
verview
:
Th
e
precursor
(PRLH
,
P81277)
for
PrR
P
gen
erates
31
an
d
20-am
in
o-acid
version
s.
Q
R
FP43
(Q
RFP,
P83859)
(n
am
ed
after
a
pyroglutam
ylated
argin
in
e-ph
en
ylalan
in
e-am
ide
peptide)
is
a
43
am
in
o
acid
peptide
derived
from
Q
R
FP
(P83859)
an
d
is
also
kn
ow
n
as
P518
or
26R
Fa.
R
FR
P
is
an
R
F
am
ide-related
pep-
tide
[794]
derived
from
a
FM
R
Fam
ide-related
peptide
precursor
(N
PV
F,
Q
9H
C
Q
7),
w
h
ich
is
cleaved
to
gen
erate
n
europeptide
SF
(N
PFF,
O
15130),
n
europeptide
R
FR
P-1
(N
PV
F,
Q
9H
C
Q
7),
n
eu-
ropeptide
R
FR
P-2
(N
PV
F,
Q
9H
C
Q
7)
an
d
n
europeptide
R
FR
P-3
(N
PV
F,Q
9H
C
Q
7)
(n
europeptide
N
PV
F).
N
om
enclature
PrRP
receptor
H
G
N
C
,U
niProt
PRLH
R,P49683
Potency
order
ofendogenous
ligands
PrRP-20
(PRLH
,P81277)
=
PrRP-31
(PRLH
,P81277)
[1099]
Endogenous
agonists
PrRP-20
(PRLH
,P81277)
[509,1099],PrRP-31
(PRLH
,P81277)
[509,1099]
Endogenous
antagonists
neuropeptide
Y
(N
PY,P01303)
(pK
i 5.4)
[1087]
Labelled
ligands
[ 125I]PrRP-20
(hum
an)
(Agonist)
[1099],[ 125I]PrRP31
(Agonist)
[501]
C
o
m
m
en
ts:Th
e
orph
an
receptor
G
PR83
(Q
9N
Y
M
4)
sh
ow
s
sequen
ce
sim
ilarities
w
ith
N
PFF1,N
PFF2,PrR
P
an
d
Q
R
FP
receptors.
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rth
er
read
in
g
o
n
P
ro
lactin
-releasin
g
p
ep
tid
e
recep
to
r
Sam
son
W
K
etal.(2006)Prolactin
releasin
g
peptide
(PrR
P):an
en
dogen
ous
regulatorofcellgrow
th
.
Peptides
27
:1099-103
[PM
ID
:16500730]
Takayan
agiY
et
al.
(2010)
R
oles
of
prolactin
-releasin
g
peptide
an
d
R
Fam
ide
related
peptides
in
th
e
con
trolof
stress
an
d
food
in
take.
FEBS
J.277
:4998-5005
[PM
ID
:21126313]
Prostanoid
receptors
G
protein
-coupled
receptors→
Prostan
oid
receptors
O
verview
:Prostan
oid
receptors
(n
o
m
en
clatu
re
as
ag
reed
b
y
th
e
N
C
-IU
P
H
A
R
Su
b
co
m
m
ittee
o
n
P
ro
stan
o
id
R
ecep
to
rs
[2132])are
activated
by
th
e
en
dogen
ous
ligan
ds
prostaglan
din
s
PG
D
2 ,
PG
E
1 ,PG
E
2
,PG
F2α
,PG
H
2 ,prostacyclin
[PG
I2 ]
an
d
th
rom
boxan
e
A
2 .
M
easurem
en
t
of
th
e
poten
cy
of
PG
I2
an
d
th
rom
boxan
e
A
2
is
h
am
pered
by
th
eir
in
stability
in
ph
ysiologicalsalt
solution
;th
ey
are
often
replaced
by
cicaprost
an
d
U
46619,respectively,in
receptor
ch
aracterization
studies.
N
om
enclature
D
P
1
receptor
D
P
2
receptor
H
G
N
C
,U
niProt
PTG
D
R,Q
13258
PTG
D
R2,Q
9Y5Y4
Potency
order
ofendogenous
ligands
PG
D
2
>
PG
E1 ≫
PG
E2
>
PG
F2α
>
PG
I2 ,throm
boxane
A
2
PG
D
2 ≫
PG
F2α
,PG
E2
>
PG
I2 ,throm
boxane
A
2
Selective
agonists
BW
245C
[173,2133,2134],L-644,698
[2133,2134]
15(R)-15-m
ethyl-PG
D
2
[747,1366,1889]
Antagonists
–
fevipiprant
(pK
d
9)
[1908,1909],ram
atroban
(pK
i 7.4)
[1889]
Selective
antagonists
laropiprant
(pK
i 10.1)
[1882],BW
A868C
(pK
i 8.6–9.3)
[173,640,2133],
O
N
O
-AE3-237
(pK
i 7.7)
[796,1974,1976]
C
AY
10471
(pIC
50
8.9)
[1684,2003]
Labelled
ligands
[ 3H
]PG
D
2
(Agonist)
[2119,2133]
[ 3H
]PG
D
2
(Agonist)
[1280,1790]
N
om
enclature
EP
1
receptor
EP
2
receptor
EP
3
receptor
EP
4
receptor
H
G
N
C
,U
niProt
PTG
ER1,P34995
PTG
ER2,P43116
PTG
ER3,P43115
PTG
ER4,P35408
Potency
order
ofendogenous
ligands
PG
E2
>
PG
E1
>
PG
F2α
,PG
I2
>
PG
D
2 ,
throm
boxane
A
2
PG
E2
=
PG
E1
>
PG
F2α
,PG
I2
>
PG
D
2 ,throm
boxane
A
2
PG
E2 ,PG
E1
>
PG
F2α
,PG
I2
>
PG
D
2 ,
throm
boxane
A
2
PG
E2
=
PG
E1
>
PG
F2α
,PG
I2
>
PG
D
2 ,throm
boxane
A
2
Endogenous
agonists
–
PG
E2
[7,1871,2119]
PG
E2
(EP
3 -IIIisoform
)
[7]
–
Agonists
17-phenyl-ω
-trinor-PG
E2
[1783]
PG
E1
[111]
m
isoprostol(m
ethylester)
(EP
3 -IIIisoform
)
[7]
–
Selective
agonists
O
N
O
-D
I-004
[1899]–
M
ouse
O
N
O
-AE1-259
[1899]–
M
ouse,
butaprost
(free
acid
form
)
[7,1871]
sulprostone
(EP
3 -IIIisoform
)
[7],O
N
O
-AE-248
[562,1206]
L902688
[563,1129],
O
N
O
-AE1-329
[562,563]
Antagonists
–
–
–
EP
4 A
(pK
i 7.6–8.5)
[1229,2195]
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N
om
enclature
EP
1
receptor
EP
2
receptor
EP
3
receptor
EP
4
receptor
Selective
antagonists
O
N
O
-8711
(pK
i 9.2)
[2079],SC
-51322
(pK
i 7.9)
[7]
PF-04418948
(PF-04418948
has
w
eaker
affinity
at
the
EP2-receptor
in
guinea-pigs)
(pK
B
8.3)
[14,157],
TG
6-129
(pK
B
8.1)
[598]
L-826266
(EP
3 -IIIisoform
(pK
i =8.04
in
the
presence
ofH
SA))
(pK
i 9.1)
[933],
O
N
O
-AE3-240
(pIC
50
8.8)
[38]–
M
ouse,
D
G
-041
(pK
i 8.4)
[931]
O
N
O
-AE3-208
(pK
i 8.5),
G
W
627368
(pK
i 7–7.1)
[2119,
2120]
Labelled
ligands
[ 3H
]PG
E2
(Agonist)
[7,1783,2119]
[ 3H
]PG
E2
(Agonist)
[7,2119]
[ 3H
]PG
E2
(Agonist)
[7,2119]
[ 3H
]PG
E2
(Agonist)
[7,420,
2107,2119]
N
om
enclature
FP
receptor
IP
receptor
TP
receptor
H
G
N
C
,U
niProt
PTG
FR,P43088
PTG
IR,P43119
TBXA2R,P21731
Potency
order
ofendogenous
ligands
PG
F2α
>
PG
D
2
>
PG
E2
>
PG
I2 ,throm
boxane
A
2
PG
I2 ≫
PG
E1
>
PG
D
2 ,PG
F2α
>
throm
boxane
A
2
throm
boxane
A
2
=
PG
H
2 ≫
PG
D
2 ,PG
E2 ,PG
F2α
,
PG
I2
Endogenous
agonists
–
PG
I2
[1804],PG
E1
[1277,1873]
–
Agonists
–
iloprost
[7,2119],treprostinil[2107]
–
Selective
agonists
fluprostenol[7],latanoprost
(free
acid
form
)
[7]
cicaprost
[7]
U
46619
[7]
Antagonists
–
–
ram
atroban
(pK
i 8)
[1944]
Selective
antagonists
AS604872
(pK
i 7.5)
[361]
RO
1138452
(pK
i 8.7)
[162],RO
3244794
(pA
2
8.5)
[162]
vapiprost
(pK
i 8.3–9.4)
[63,1216],SQ
-29548
(pK
i
8.1–9.1)
[7,1907,2119]
Labelled
ligands
[ 3H
]PG
F2α
(Agonist)
[7,8,2119],
[ 3H
](+)-fluprostenol(Agonist)
[ 3H
]iloprost
(Agonist)
[7,172,2107,2119]
[ 125I]SAP
(Antagonist)
(pK
d
7.7–9.3)
[1415],
[ 125I]BO
P
(Agonist)
[1381],[ 3H
]SQ
-29548
(Antagonist)
(pK
d
7.4–8.2)
[7,2119]
C
o
m
m
en
ts:
W
h
ilst
cicaprost
is
selective
for
IP
receptors,it
does
exh
ibit
m
oderate
agon
ist
poten
cy
at
EP
4
receptors
[7].
A
part
from
IP
receptors,
iloprost
also
bin
ds
to
EP
1
receptors.
Th
e
IP
receptor
agon
ist
treprostin
ilbin
ds
also
to
h
um
an
EP
2
an
d
D
P
1
re-
ceptors
w
ith
h
igh
affin
ity
(pK
i 8.44
an
d
8.36,respectively)[2107].
Th
e
EP
1
agon
ist
17-ph
en
yl-ω
-trin
or-PG
E
2
also
sh
ow
s
agon
ist
activity
at
EP
3
receptors.
Butaprost
an
d
SC
46275
m
ay
require
de-
esterification
w
ith
in
tissues
to
attain
full
agon
ist
poten
cy.
Th
ere
is
eviden
ce
for
subtypes
of
FP
[1171]
an
d
TP
receptors
[1050,
1637].
m
R
N
A
for
th
e
EP
3
receptor
un
dergoes
altern
ative
splicin
g
to
produce
varian
ts
w
h
ich
can
in
terfere
w
ith
sign
allin
g
[1509]
or
gen
erate
com
plex
pattern
s
of
G
-protein
(G
i/o ,
G
q/11 ,
G
s
an
d
G
12,13 )
couplin
g
(e.g.
[1042,1433]).
Th
e
n
um
ber
of
EP
3
receptor
(protein
)
varian
ts
are
variable
depen
din
g
on
species,
w
ith
five
in
h
um
an
,
th
ree
in
rat
an
d
th
ree
in
m
ouse.
Putative
receptor(s)
for
prostam
ide
F
(w
h
ich
as
yet
lack
m
olecular
correlates)
an
d
w
h
ich
preferen
tially
recogn
ize
PG
F2-1-eth
an
olam
ide
an
d
its
an
alogues
(e.g.
Bim
atoprost)
h
ave
been
iden
tified,
togeth
er
w
ith
m
oderate-
poten
cy
an
tagon
ists
(e.g.A
G
N
211334)[2131].Th
e
free
acid
form
ofA
L-12182,A
L12180,used
in
in
vitro
studies,h
as
a
EC
50
of15n
M
w
h
ich
is
th
e
con
cen
tration
ofth
e
com
poun
d
givin
g
h
alf-m
axim
al
stim
ulation
of
in
ositol
ph
osph
ate
turn
over
in
H
EK
-293
cells
expressin
g
th
e
h
um
an
FP
receptor
[1784].R
eferen
ces
given
alon
g-
side
th
e
TP
receptor
agon
ists
I-BO
P
[1295]
an
d
STA
2
[63]
use
h
u-
m
an
platelets
as
th
e
source
of
TP
receptors
for
com
petition
radio-
ligan
d
bin
din
g
assays
to
determ
in
e
th
e
in
dicated
activity
values.
Ph
arm
acological
eviden
ce
for
a
secon
d
IP
receptor,
den
oted
IP
2 ,
in
th
e
cen
tral
n
ervous
system
[1924,
2082]
an
d
in
th
e
BEA
S-2B
h
um
an
airw
ay
epith
elial
cell
lin
e
[2122]
is
available.
Th
is
receptor
is
selectively
activated
by
15R
-17,18,19,
20-tetran
or-16-m
-tolyl-isocarbacyclin
(15R
-TIC
)
an
d
15R
-D
eoxy
17,18,19,20-tetran
or-16-m
-tolyl-isocarbacyclin
(15-deoxy-TIC
).
H
ow
ever,
m
olecular
biological
eviden
ce
for
an
IP
2
subtype
is
curren
tly
lackin
g.
Searchable
database:http://w
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Fu
rth
er
read
in
g
o
n
P
ro
stan
o
id
recep
to
rs
W
oodw
ard
D
F
et
al.
(2011)
In
tern
ation
al
un
ion
of
basic
an
d
clin
ical
ph
arm
acology.
LX
X
X
III:
classification
of
prostan
oid
receptors,
updatin
g
15
years
of
progress.
Pharm
acol.
Rev.
63
:
471-538
[PM
ID
:21752876]
Proteinase-activated
receptors
G
protein
-coupled
receptors→
Protein
ase-activated
receptors
O
verview
:
Protein
ase-activated
receptors
(PA
R
s,
n
o
m
en
cla-
tu
re
as
ag
reed
b
y
th
e
N
C
-IU
P
H
A
R
Su
b
co
m
m
ittee
o
n
P
ro
tein
ase-activated
R
ecep
to
rs
[809])
are
un
ique
m
em
bers
ofth
e
G
PC
R
superfam
ily
activated
by
proteolytic
cleavage
ofth
eir
am
in
o
term
in
alexodom
ain
s.A
gon
ist
protein
ase-in
duced
h
ydrol-
ysis
un
m
asks
a
teth
ered
ligan
d
(TL)
at
th
e
exposed
am
in
o
term
i-
n
us,w
h
ich
acts
in
tram
olecularly
atth
e
bin
din
g
site
in
th
e
body
of
th
e
receptor
to
effect
tran
sm
em
bran
e
sign
allin
g.
TL
sequen
ces
at
h
um
an
PA
R
1-4
are
SFLLR
N
-N
H
2 ,SLIG
K
V
-N
H
2 ,TFR
G
A
P-N
H
2
an
d
G
Y
PG
Q
V
-N
H
2 ,
respectively.
W
ith
th
e
exception
of
PA
R
3,
th
ese
syn
th
etic
peptide
sequen
ces
(ascarboxylterm
in
alam
ides)are
able
to
actas
agon
ists
atth
eir
respective
receptors.Severalprotein
ases,
in
cludin
g
n
eutroph
ilelastase,cath
epsin
G
an
d
ch
ym
otrypsin
can
h
ave
in
h
ibitory
effects
atPA
R
1
an
d
PA
R
2
such
th
atth
ey
cleave
th
e
exodom
ain
of
th
e
receptor
w
ith
out
in
ducin
g
activation
of
G
α
q-
coupled
calcium
sign
allin
g,th
ereby
preven
tin
g
activation
by
acti-
vatin
g
protein
asesbutn
otby
agon
istpeptides.N
eutroph
ilelastase
(N
E)cleavage
ofPA
R
1
an
d
PA
R
2
can
h
ow
ever
activate
M
A
P
kin
ase
sign
alin
g
by
exposin
g
a
TL
th
at
is
differen
t
from
th
e
on
e
revealed
by
trypsin
[1624].
PA
R
2
ectivation
by
N
E
regulates
in
flam
m
ation
an
d
pain
respon
ses[1397,2217]an
d
triggersm
ucin
secretion
from
airw
ay
epith
elialcells
[2220].
N
om
enclature
PAR1
PAR2
PAR3
PAR4
H
G
N
C
,U
niProt
F2R,P25116
F2RL1,P55085
F2RL2,O
00254
F2RL3,Q
96RI0
Agonist
proteases
throm
bin
(F2,P00734),activated
protein
C
(PRO
C,P04070),
m
atrix
m
etalloproteinase
1
(M
M
P1,
P45452),m
atrix
m
etalloproteinase
13
(M
M
P13,P45452)
[73]
Trypsin,tryptase,TF/VIIa,X
a
throm
bin
(F2,P00734)
throm
bin
(F2,P00734),
trypsin,cathepsin
G
(CTSG
,
P08311)
Agonists
F16357
–
–
–
Selective
agonists
TFLLR-N
H
2
[355]
AC
264613
[1767],AY77
[2178],AC
-55541
[1767],G
B110
[104],
2-furoyl-LIG
RLO
-am
ide
[1305],SLIG
KV-N
H
2
[1134],SLIG
RL-N
H
2
[1134]
–
AYPG
KF-N
H
2,G
YPG
KF-N
H
2,
G
YPG
Q
V-N
H
2
Selective
antagonists
vorapaxar
(pK
i 8.1)
[295],atopaxar
(pIC
50
7.7)
[1024],RW
J-56110
(pIC
50
6.4)
[49]
G
B88
(pIC
50
5.7)
[1886],P2pal18s
[1776]
–
YD
-3
(pIC
50
6.9)
[2091],
M
L354
(pIC
50
6.8)
[2091]
Labelled
ligands
[ 3H
]haTRAP
(Agonist)
[17]
2-furoyl-LIG
RL[N
-(Alexa
Fluor
594)-O
]-N
H
2
(Agonist)
[810],
2-furoyl-LIG
RL[N
[ 3H
]propionyl]-O
-N
H
2
(Agonist)
[810],
[ 3H
]2-furoyl-LIG
RL-N
H
2
(Selective
Agonist)
[946],
trans-cinnam
oyl-LIG
RLO
[N
-[ 3H
]propionyl]-N
H
2
(Agonist)
[28]
–
–
C
om
m
ents
TFLLR-N
H
2
is
selective
relative
to
the
PAR
2
receptor
[159,958].
2-Furoyl-LIG
RLO
-N
H
2
activity
w
as
m
easured
via
calcium
m
obilisation
in
H
EK
293
cells
w
hich
constitutively
coexpress
hum
an
PAR
1
and
PAR
2 .
–
–
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C
o
m
m
en
ts:
En
dogen
ous
serin
e
proteases
(EC
3.4.21.)
ac-
tive
at
th
e
protein
ase-activated
receptors
in
clude:
th
rom
bin
(F2,
P00734),
gen
erated
by
th
e
action
of
Factor
X
(F10,
P00742)
on
liver-derived
proth
rom
bin
(F2,P00734);trypsin
,gen
erated
by
th
e
action
ofen
terokin
ase
(T
M
PRSS15,P98073)on
pan
creatic-derived
trypsin
ogen
(PRSS1,P07477);tryptase,a
fam
ily
of
en
zym
es
(α
/β1
T
PSA
B1,Q
15661
;γ1
T
PSG
1,Q
9N
R
R
2;δ1
T
PSD
1,Q
9BZJ3)secreted
from
m
ast
cells;
cath
epsin
G
(C
T
SG
,
P08311)
gen
erated
from
leukocytes;
liver-derived
protein
C
(PRO
C
,
P04070)
gen
erated
in
plasm
a
by
th
rom
bin
(F2,P00734)an
d
m
atrix
m
etalloprotein
ase
1
(M
M
P1,P45452).
Fu
rth
er
read
in
g
o
n
P
ro
tein
ase-activated
recep
to
rs
A
dam
s
M
N
et
al.
(2011)
Structure,
fun
ction
an
d
path
oph
ysiology
of
protease
activated
receptors.
Pharm
acol.T
her.130
:248-82
[PM
ID
:21277892]
C
an
to
I
et
al.
(2012)
A
llosteric
m
odulation
of
protease-activated
receptor
sign
alin
g.
M
ini
Rev
M
ed
C
hem
12
:804-11
[PM
ID
:22681248]
G
arcía
PS
et
al.
(2010)
Th
e
role
of
th
rom
bin
an
d
protease-activated
receptors
in
pain
m
ech
an
ism
s.
T
hrom
b.H
aem
ost.103
:1145-51
[PM
ID
:20431855]
H
ollen
berg
M
D
et
al.
(2002)
In
tern
ation
al
U
n
ion
of
Ph
arm
acology.
X
X
V
III.
Protein
ase-activated
receptors.Pharm
acol.Rev.54
:203-17
[PM
ID
:12037136]
R
am
ach
an
dran
R
et
al.
(2012)
Targetin
g
protein
ase-activated
receptors:
th
erapeutic
poten
tial
an
d
ch
allen
ges.
N
atRev
D
rug
D
iscov
11
:69-86
[PM
ID
:22212680]
Soh
U
J
et
al.
(2010)
Sign
al
tran
sduction
by
protease-activated
receptors.
Br.
J.
Pharm
acol.
160
:
191-203
[PM
ID
:20423334]
Q
RFP
receptor
G
protein
-coupled
receptors→
Q
R
FP
receptor
O
verview
:
Th
e
h
um
an
gen
e
en
codin
g
th
e
Q
R
FP
receptor
(Q
R
FPR
,
also
kn
ow
n
as
th
e
peptide
P518
receptor),
previously
design
ated
as
an
orph
an
G
PC
R
receptor
w
as
iden
tified
in
2001
by
Lee
et
al.
from
a
h
ypoth
alam
us
cD
N
A
library
[1131].
H
ow
ever,th
e
reported
cD
N
A
(A
F411117)
is
a
ch
im
era
w
ith
bases
1-127
derived
from
ch
rom
osom
e
1
an
d
bases
155-1368
derived
from
ch
rom
osom
e
4.
W
h
en
corrected,
Q
R
FPR
(also
referred
to
as
SP9155
or
A
Q
27)
en
codes
a
431
am
in
o
acid
protein
th
at
sh
ares
sequen
ce
sim
ilarities
in
th
e
tran
sm
em
bran
e
span
n
in
g
region
s
w
ith
oth
er
peptide
receptors.
Th
ese
in
clude
n
europeptide
FF2
(38%
),n
europeptide
Y
2
(37%
)
an
d
galan
in
G
al1
(35%
)
receptors.
N
om
enclature
Q
RFP
receptor
H
G
N
C
,U
niProt
Q
RFPR,Q
96P65
Endogenous
agonists
Q
RFP43
(Q
RFP,P83859)
[311,587,1923]–
Rat,Q
RFP26
(Q
RFP)
[311,910]
Agonists
LV-2172
[1448]
Selective
antagonists
com
pound
25e
(pIC
50
7.3)
[628,629]
Labelled
ligands
[ 125I]Q
RFP43
(hum
an)
(Agonist)
[587,1063,1923]
C
o
m
m
en
ts:Th
e
orph
an
receptor
G
PR83
(9N
Y
M
4)
sh
ow
s
sequen
ce
sim
ilarities
w
ith
th
e
Q
R
FP
receptor,as
w
ellas
w
ith
th
e
N
PFF1,N
PFF2,an
d
PrR
P
receptors.
Fu
rth
er
read
in
g
o
n
Q
R
FP
recep
to
r
Fukusum
iS
etal.(2006)
R
ecen
t
advan
ces
in
m
am
m
alian
R
Fam
ide
peptides:th
e
discovery
an
d
fun
ction
alan
alyses
of
PrR
P,R
FR
Ps
an
d
Q
R
FP.Peptides
27
:1073-86
[PM
ID
:16500002]
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Relaxin
fam
ily
peptide
receptors
G
protein
-coupled
receptors→
R
elaxin
fam
ily
peptide
receptors
O
verview
:
R
elaxin
fam
ily
peptide
receptors
(R
X
FP,n
o
m
en
cla-
tu
re
as
ag
reed
b
y
th
e
N
C
-IU
P
H
A
R
Su
b
co
m
m
ittee
o
n
R
e-
lax
in
fam
ily
p
ep
tid
e
recep
to
rs
[112,
713])
m
ay
be
divided
in
to
tw
o
pairs,
R
X
FP1/2
an
d
R
X
FP3/4.
En
dogen
ous
agon
ists
at
th
ese
receptors
are
a
n
um
ber
of
h
eterodim
eric
peptide
h
or-
m
on
es
structurally
related
to
in
sulin
:
relaxin
-1
(RLN
1,
P04808),
relaxin
(RLN
2,
P04090),
relaxin
-3
(RLN
3,
Q
8W
X
F3)
(also
kn
ow
n
as
IN
SL7),
in
sulin
-like
peptide
3
(IN
SL3
(IN
SL3,
P51460))
an
d
IN
SL5
(IN
SL5,Q
9Y
5Q
6).
Species
h
om
ologues
of
relaxin
h
ave
distin
ct
ph
arm
acology
–
relaxin
(RLN
2,P04090)
in
teracts
w
ith
R
X
FP1,R
X
FP2
an
d
R
X
FP3,
w
h
ereas
m
ouse
an
d
rat
relaxin
selectively
bin
d
to
an
d
activate
R
X
FP1
[1755]an
d
porcin
e
relaxin
m
ay
h
ave
a
h
igh
erefficacy
th
an
h
um
an
relaxin
(RLN
2,P04090)[714].R
elaxin
-3
(RLN
3,Q
8W
X
F3)
h
as
differen
tial
affin
ity
for
R
X
FP2
betw
een
species;
m
ouse
an
d
rat
R
X
FP2
h
ave
a
h
igh
er
affin
ity
for
relaxin
-3
(RLN
3,
Q
8W
X
F3)
[1754].
A
t
least
tw
o
bin
din
g
sites
h
ave
been
iden
tified
on
R
X
FP1
an
d
R
X
FP2:
a
h
igh
-affin
ity
site
in
th
e
leucin
e-rich
repeat
region
of
th
e
ectodom
ain
an
d
a
som
ew
h
at
low
er-affin
ity
site
located
in
th
e
surface
loops
of
th
e
tran
sm
em
bran
e
dom
ain
[714,1885].Th
e
un
ique
N
-term
in
alLD
La
m
odule
ofR
X
FP1
an
d
R
X
FP2
is
essen
tial
for
receptor
sign
allin
g
[1756].
N
om
enclature
RX
FP1
RX
FP2
RX
FP3
RX
FP4
H
G
N
C
,U
niProt
RXFP1,Q
9H
BX
9
RXFP2,Q
8W
X
D
0
RXFP3,Q
9N
SD
7
RXFP4,Q
8TD
U
9
Potency
order
ofendogenous
ligands
relaxin
(RLN
2,P04090)
=
relaxin-1
(RLN
1,P04808)
>
relaxin-3
(RLN
3,
Q
8W
X
F3)
[1885]
IN
SL3
(IN
SL3,P51460)
>
relaxin
(RLN
2,P04090)≫
relaxin-3
(RLN
3,Q
8W
X
F3)
[1072,1885]
relaxin-3
(RLN
3,Q
8W
X
F3)
>
relaxin-3
(B
chain)
(RLN
3,
Q
8W
X
F3)
>
relaxin
(RLN
2,
P04090)
[1186]
IN
SL5
(IN
SL5,Q
9Y5Q
6)
=
relaxin-3
(RLN
3,Q
8W
X
F3)
>
relaxin-3
(B
chain)
(RLN
3,Q
8W
X
F3)
[1184,1185]
Endogenous
antagonists
–
–
IN
SL5
(IN
SL5,Q
9Y5Q
6)
(pK
i 7)
[2223]
–
Antagonists
B-R13/17K
H
2
relaxin
(pEC
50
5.7–6.7)
[827,
1446]
–
R3(B$
23-27)R/I5
chim
eric
peptide
(pIC
50
9.2)
[1064]
R3(B$
23-27)R/I5
chim
eric
peptide
(pIC
50
8–8.6)
[749,1064]
Selective
antagonists
–
A(9-26)IN
SL3
(pK
i 9.1)
[826],A(10-24)IN
SL3
(pK
i
8.7)
[826],A(C
10/15S)IN
SL3
(pK
i 8.6)
[2210],
IN
SL3
B
chain
dim
er
analogue
8
(pK
i 8.5)
[1781],
A($
10/15C
)IN
SL3
(pK
i 8.3)
[2210],
cyclic
IN
SL3
B-chain
analogue
6
(pK
i 6.7)
[1779],
IN
SL3
B-chain
analogue
(pK
i 5.1)
[434],
(des
1-8)
A-chain
IN
SL3
analogue
[262]
m
inim
ised
relaxin-3
analogue
3
(pK
i 7.6)
[1777],R3-B1-22R
(pK
i
7.4)
[749]
m
inim
ised
relaxin-3
analogue
3
(pIC
50
6.6)
[1777]
Allosteric
m
odulators
M
L290
(Agonist)
(pEC
50
7)
[2146,2149]
–
–
–
Labelled
ligands
[ 33P]relaxin
(hum
an)
(Agonist)
[714,1885],
europium
-labelled
relaxin
(Agonist)
[1778],
[ 125I]relaxin
(hum
an)
(Agonist)
[ 125I]IN
SL3
(hum
an)
(Agonist)
[1395],
[ 33P]relaxin
(hum
an)
(Agonist)
[714,1885]
[ 125I]relaxin-3
(hum
an)
(Agonist)
[1186],
[ 125I]relaxin-3-B/IN
SL5
A
chim
era
(Agonist)
[1184],
europium
-labelled
relaxin-3-B/IN
SL5
A
chim
era
(Agonist)
[749]
[ 125I]relaxin-3
(hum
an)
(Agonist)
[1185],
[ 125I]relaxin-3-B/IN
SL5
A
chim
era
(Agonist)
[1184],
europium
-labelled
m
ouse
IN
SL5
(Agonist)
[126],
europium
-labelled
relaxin-3-B/IN
SL5
A
chim
era
(Agonist)
[749],
europium
-labelled
IN
SL5
(pK
d
8.3)
[749]
C
om
m
ents
–
europium
-labelled
IN
SL3
is
a
fluorescent
ligand
for
this
receptor
(K
d =1nM
)
[1780].
–
–
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C
o
m
m
en
ts:
R
elaxin
is
th
e
cogn
ate
peptide
ligan
d
for
R
X
FP1
an
d
is
in
exten
ded
Ph
ase
III
clin
ical
trials
for
th
e
treatm
en
t
of
acute
h
eart
failure
[1322].
R
elaxin
h
as
vasodilatory,
an
ti-fibrotic,
an
giogen
ic,
an
ti-apoptotic
an
d
an
ti-in
flam
m
atory
effects.
Sm
all
m
olecule
allosteric
agon
ists
such
as
M
L290
h
ave
been
developed
[1787,2149].Th
e
an
tifibrotic
action
s
ofrelaxin
are
depen
den
t
on
th
e
an
gioten
sin
receptor
A
T
2
[344].R
X
FP2
an
d
its
cogn
ate
ligan
d
IN
SL3
h
ave
a
m
ore
specialized
role
w
ith
m
utation
s
reported
in
patien
ts
w
ith
cryptorch
idism
[538].
cA
M
P
elevation
is
th
e
m
ajor
sign
allin
g
path
w
ay
for
R
X
FP1
an
d
R
X
FP2
[834,
835],
but
R
X
FP1
also
activates
M
A
P
kin
ases,n
itric
oxide
sign
allin
g,tyrosin
e
kin
ase
ph
osph
orylation
an
d
relaxin
can
in
teract
w
ith
glucocorticoid
re-
ceptors
[716].R
X
FP1
sign
allin
g
in
volves
lipid
rafts,residues
in
th
e
C
-term
in
usofth
e
receptoran
d
activation
ofph
osph
atidylin
ositol-
3-kin
ase
[717]
an
d
pre-assem
bled
protein
com
plexes
[715].
R
eceptor
expression
profiles
suggest
th
at
R
X
FP3
is
a
brain
n
eu-
ropeptide
receptor
an
d
R
X
FP4
a
gut
h
orm
on
e
receptor
w
ith
th
e
relaxin
-3/R
X
FP3
system
m
odulatin
g
feedin
g
[596,
597,
749,
1777,
1830],
an
xiety
[1694,
2204],
an
d
rew
ard
an
d
m
otivated
goal-directed
beh
aviours
[821,
1694,
2055].
R
elaxin
-3
(RLN
3,
Q
8W
X
F3)
is
an
agon
ist
at
R
X
FP3
an
d
R
X
FP4
w
h
ereas
IN
SL5
(IN
SL5,
Q
9Y
5Q
6)
is
an
agon
ist
at
R
X
FP4
an
d
a
w
eak
an
tagon
ist
at
R
X
FP3.
U
n
like
R
X
FP1
an
d
R
X
FP2,
both
R
X
FP3
an
d
R
X
FP4
are
en
coded
by
a
sin
gle
exon
.
IN
SL5
is
secreted
from
en
teroen
-
docrin
e
L
cells
an
d
th
e
IN
SL5/R
X
FP4
system
con
trols
food
in
take
an
d
glucose
h
om
eostasis
[685].
R
X
FP3
an
d
R
X
FP4
couple
to
G
i/o
an
d
in
h
ibit
aden
ylyl
cyclase
[1186,
2014],
an
d
also
cause
Erk1/2
ph
osph
orylation
[2014].
R
X
FP4
also
causes
ph
osph
orylation
of
p38M
A
PK
,
A
kt
an
d
S6R
P
[51].
Th
ere
is
eviden
ce
th
at
at
R
X
FP3,
relaxin
(RLN
2,P04090)is
a
biased
ligan
d
com
pared
to
th
e
cogn
ate
ligan
d
relaxin
-3.
Fu
rth
er
read
in
g
o
n
R
elax
in
fam
ily
p
ep
tid
e
recep
to
rs
Bath
gate
R
A
et
al.
(2013)
R
elaxin
fam
ily
peptides
an
d
th
eir
receptors.
Physiol.
Rev.
93
:
405-80
[PM
ID
:23303914]
D
u
X
J
et
al.
(2010)
C
ardiovascular
effects
of
relaxin
:
from
basic
scien
ce
to
clin
icalth
erapy.
N
at
Rev
C
ardiol7
:48-58
[PM
ID
:19935741]
H
alls
M
L
et
al.
(2015)
In
tern
ation
al
U
n
ion
of
Basic
an
d
C
lin
ical
Ph
arm
acology.
X
C
V.
R
ecen
t
ad-
van
ces
in
th
e
un
derstan
din
g
of
th
e
ph
arm
acology
an
d
biological
roles
of
relaxin
fam
ily
pep-
tide
receptors
1-4,
th
e
receptors
for
relaxin
fam
ily
peptides.
Pharm
acol.
Rev.
67
:
389-440
[PM
ID
:25761609]
Ivell
R
et
al.
(2011)
R
elaxin
fam
ily
peptides
in
th
e
m
ale
reproductive
system
–a
critical
appraisal.
M
ol.H
um
.Reprod.17
:71-84
[PM
ID
:20952422]
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Som
atostatin
receptors
G
protein
-coupled
receptors→
Som
atostatin
receptors
O
verview
:
Som
atostatin
(som
atotropin
release
in
h
ibitin
g
factor)
is
an
abun
dan
t
n
europeptide,
w
h
ich
acts
on
five
subtypes
of
som
atostatin
receptor
(SST
1 -SST
5 ;
n
o
m
en
clatu
re
as
ag
reed
b
y
th
e
N
C
-IU
P
H
A
R
Su
b
co
m
m
ittee
o
n
So
m
ato
statin
R
ecep
to
rs
[829]).
A
ctivation
of
th
ese
receptors
produces
a
w
ide
ran
ge
of
ph
ysiological
effects
th
rough
out
th
e
body
in
cludin
g
th
e
in
h
ibition
of
secretion
of
m
an
y
h
orm
on
es.
En
dogen
ous
ligan
ds
for
th
ese
receptors
are
som
atostatin
-14
(SR
IF-14
(SST
,P61278))
an
d
som
atostatin
-28
(SR
IF-28
(SST
,P61278)).
C
ortistatin
-14
{M
ouse,R
at}
h
as
also
been
suggested
to
be
an
en
dogen
ous
ligan
d
for
som
atostatin
receptors
[427].
N
om
enclature
SST
1
receptor
SST
2
receptor
SST
3
receptor
SST
4
receptor
SST
5
receptor
H
G
N
C
,U
niProt
SSTR1,P30872
SSTR2,P30874
SSTR3,P32745
SSTR4,P31391
SSTR5,P35346
Agonists
pasireotide
[1740]
pasireotide
[1740]
pasireotide
[1740],
vapreotide
[238,1540,
1807]
N
N
C
269100
[1197]
pasireotide
[1740]
Selective
agonists
L-797,591
[1669],
D
es-Ala 1,2,5-[D
-Trp
8,IAm
p
9]SRIF
[512]
L-054,522
[2172],BIM
23027
[283],
octreotide
[238,1540,1805,1806,1807,
2172]
L-796,778
[1669]
L-803,087
[1669]
BIM
23052
[1325,1805,1806,
1807],L-817,818
[1669]
Selective
antagonists
SRA880
(pK
d
8–8.1)
[831]
[D
-Tyr 8]C
YN
154806
(pK
d
8.1–8.9)
[1478]
N
VP
AC
Q
090
(pK
i 7.9)
[832]
–
–
Labelled
ligands
–
[ 125I]Tyr 3
SM
S
201-995
(Agonist)
[1805,
1806],[ 125I]BIM
23027
(Agonist)
[811]–
Rat
–
–
[ 125I]Tyr 3
SM
S
201-995
(Agonist)
[1805,1806]
C
o
m
m
en
ts:[ 125I]Tyr 11-SR
IF-14,[ 125I]LTT-SR
IF-28,[ 125I]C
G
P
23996
an
d
[ 125I]Tyr 10-C
ST14
m
ay
be
used
to
labelsom
atostatin
receptors
n
on
selectively.A
n
um
berofn
on
peptide
subtype-selective
agon
ists
h
ave
been
syn
th
esised
[1669].
O
ctreotide
an
d
lan
reotide
are
bein
g
used
in
th
e
treatm
en
t
of
SST
2 -expressin
g
n
euroen
docrin
e
tum
ors
an
d
pasireotide
for
SST
5 -expressin
g
n
euroen
docrin
e
tum
ors.
A
n
ovel
peptide
som
atostatin
an
alogue,veldoreotide
(som
atoprim
),h
as
affin
ity
for
SST
2 ,SST
4
an
d
SST
5
receptors
an
d
is
a
poten
t
in
h
ibitor
of
G
H
secretion
[1586,1793].
Fu
rth
er
read
in
g
o
n
So
m
ato
statin
recep
to
rs
C
olao
A
et
al.
(2011)
R
esistan
ce
to
som
atostatin
an
alogs
in
acrom
egaly.
Endocr.
Rev.
32
:
247-71
[PM
ID
:21123741]
H
oyerD
etal.(2000)Som
atostatin
receptors.In
T
he
IU
PH
A
R
C
om
pendium
ofReceptorC
haracterization
and
C
lassification,2nd
edn.Edited
by
W
atson
SP,G
irdleston
e
D
:IU
PH
A
R
M
edia:354-364
Sch
ulz
S
etal.(2014)Fin
e-tun
in
g
som
atostatin
receptorsign
allin
g
by
agon
ist-selective
ph
osph
oryla-
tion
an
d
deph
osph
orylation
:IU
PH
A
R
R
eview
5.Br.J.Pharm
acol.171
:1591-9
[PM
ID
:24328848]
W
eckbecker
G
etal.(2003)O
pportun
ities
in
som
atostatin
research
:biological,ch
em
icalan
d
th
era-
peutic
aspects.
N
atRev
D
rug
D
iscov
2
:999-1017
[PM
ID
:14654798]
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Succinate
receptor
G
protein
-coupled
receptors→
Succin
ate
receptor
O
verview
:
N
o
m
en
clatu
re
as
reco
m
m
en
d
ed
b
y
N
C
-IU
P
H
A
R
[414].
Th
e
Succin
ate
receptor
h
as
been
iden
tified
as
bein
g
activated
by
ph
ysiologicallevels
of
th
e
K
rebs’cycle
in
term
ediate
succin
ate
an
d
oth
er
dicarboxylic
acids
such
as
m
aleate
in
2004.
Sin
ce
its
pairin
g
w
ith
its
en
dogen
ous
ligan
d,
th
e
receptor
h
as
been
th
e
focus
of
in
ten
sive
research
an
d
its
role
h
as
been
eviden
ced
in
various
(path
o)ph
ysiologicalprocesses
such
as
regulation
of
ren
in
production
,retin
alan
giogen
esis
or
im
m
un
e
respon
se.
N
om
enclature
succinate
receptor
H
G
N
C
,U
niProt
SU
CN
R1,Q
9BX
A5
Endogenous
agonists
succinic
acid
[762,1854]
C
o
m
m
en
ts:
In
h
um
an
s,th
ere
is
th
e
possibility
oftw
o
open
-readin
g
fram
es
(O
R
Fs)for
SU
C
N
R1,allow
in
g
th
e
gen
eration
of330
or
334
am
in
o
acid
protein
s
W
itten
berger
etal.[2127]n
oted
th
atth
e
330-A
A
protein
w
as
m
ore
likely
to
be
expressed
given
th
e
K
ozak
sequen
ce
surroun
din
g
th
e
secon
d
A
TG
.Som
e
databases
report
SU
C
N
R
1
as
bein
g
334-A
A
lon
g.
Fu
rth
er
read
in
g
o
n
Su
ccin
ate
recep
to
r
A
riza
A
C
et
al.
(2012)
Th
e
succin
ate
receptor
as
a
n
ovel
th
erapeutic
target
for
oxidative
an
d
m
etabolic
stress-related
con
dition
s.FrontEndocrinol(Lausanne)3
:22.[PM
ID
:22649411]
de
C
astro
Fon
seca
M
etal.(2016)G
PR
91:expan
din
g
th
e
fron
tiers
ofK
rebs
cycle
in
term
ediates.C
ell
C
om
m
un.Signal14
:3
[PM
ID
:26759054]
G
ilissen
J
etal.(2016)
In
sigh
t
in
to
SU
C
N
R
1
(G
PR
91)
structure
an
d
fun
ction
.
Pharm
acol.T
her.159
:
56-65
[PM
ID
:26808164]
Peti-Peterdi
J.(2010)
H
igh
glucose
an
d
ren
in
release:
th
e
role
of
succin
ate
an
d
G
PR
91.
K
idney
Int.
78
(12):1214-7.[PM
ID
:20861827]
Tachykinin
receptors
G
protein
-coupled
receptors→
Tach
ykin
in
receptors
O
verview
:
Tach
ykin
in
receptors
(p
ro
visio
n
al
n
o
m
en
cla-
tu
re
as
reco
m
m
en
d
ed
b
y
N
C
-IU
P
H
A
R
[557])
are
activated
by
th
e
en
dogen
ous
peptides
substan
ce
P
(TA
C
1,
P20366)
(SP),
n
eurokin
in
A
(TA
C
1,
P20366)
(N
K
A
;
previously
kn
ow
n
as
sub-
stan
ce
K
,
n
eurokin
in
α
,
n
eurom
edin
L),
n
eurokin
in
B
(TA
C
3,
Q
9U
H
F0)
(N
K
B;
previously
kn
ow
n
as
n
eurokin
in
β,
n
eurom
edin
K
),
n
europeptide
K
(TA
C
1,
P20366)
an
d
n
europeptide
γ
(TA
C
1,
P20366)(N
-term
in
ally
exten
ded
form
s
ofn
eurokin
in
A
).Th
e
n
eu-
rokin
in
s
(A
an
d
B)
are
m
am
m
alian
m
em
bers
of
th
e
tach
ykin
in
fam
ily,
w
h
ich
in
cludes
peptides
of
m
am
m
alian
an
d
n
on
m
am
-
m
alian
origin
con
tain
in
g
th
e
con
sen
sus
sequen
ce:Ph
e-x-G
ly-Leu-
M
et.M
arked
species
differen
ces
in
in
vitro
ph
arm
acology
exist
for
allth
ree
receptors,in
th
e
con
text
of
n
on
peptide
ligan
ds.
A
n
tago-
n
ists
such
as
aprepitan
t
an
d
fosaprepitan
t
w
ere
approved
by
FD
A
an
d
EM
A
,
in
com
bin
ation
w
ith
oth
er
an
tiem
etic
agen
ts,
for
th
e
preven
tion
of
n
ausea
an
d
vom
itin
g
associated
w
ith
em
etogen
ic
can
cer
ch
em
oth
erapy.
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N
om
enclature
N
K
1
receptor
N
K
2
receptor
N
K
3
receptor
H
G
N
C
,U
niProt
TACR1,P25103
TACR2,P21452
TACR3,P29371
Potency
order
ofendogenous
ligands
substance
P
(TAC1,P20366)
>
neurokinin
A
(TAC1,
P20366)
>
neurokinin
B
(TAC3,Q
9U
H
F0)
neurokinin
A
(TAC1,P20366)
>
neurokinin
B
(TAC3,
Q
9U
H
F0)≫
substance
P
(TAC1,P20366)
neurokinin
B
(TAC3,Q
9U
H
F0)
>
neurokinin
A
(TAC1,P20366)
>
substance
P
(TAC1,P20366)
Agonists
substance
P-O
M
e
[1960]
–
–
Selective
agonists
[Sar 9,M
et(O
2 ) 11]SP
[1960],septide
[130,746],
[Pro
9]SP
[1975]–
Rat
[Lys 5,M
e-Leu
9,N
le 10]N
KA-(4-10)
[1292]–
Rat,G
R64349
[432]–
Rat,[βAla 8]neurokinin
A-(4-10)
[505]
[Phe(M
e) 7]neurokinin
B
[1717,1718],senktide
[1717,1718,1960]
Selective
antagonists
aprepitant
(pK
i 10.1)
[709,710],C
P
99994
(pK
i
9.3–9.7)
[53,1718],RP67580
(pIC
50
7.7)
[555]
G
R94800
(pK
i 9.8)
[206],saredutant
(pK
i 9.4–9.7)
[53,
505,1718],G
R
159897
(pK
d
7.8–9.5)
[137,505,1837],
M
EN
10627
(pK
i 9.2)
[638],nepadutant
(pK
i 8.5–8.7)
[284,
358]
osanetant
(pK
i 8.4–9.7)
[53,116,357,504,941,
1518,1717,1718,1960],talnetant
(pK
i 7.4–9)
[133,639,1717,1718],PD
157672
(pIC
50
7.8–7.9)
[168,1960]
Labelled
ligands
[ 125I]L703,606
(Antagonist)
(pK
d
9.5)
[566],
[ 125I]BH
-[Sar 9,M
et(O
2 ) 11]SP
(Agonist)
[1979]–
Rat,[ 3H
]SP
(hum
an,m
ouse,rat)
(Agonist)
[84],
[ 125I]SP
(hum
an,m
ouse,rat)
(Agonist),
[ 18F]SPA-RQ
(Antagonist)
[332]
[ 3H
]saredutant
(Antagonist)
(pK
d
9.7)
[683]–
Rat,
[ 125I]N
KA
(hum
an,m
ouse,rat)
(Agonist)
[2077],
[ 3H
]G
R100679
(Antagonist)
(pK
d
9.2)
[705]
[ 3H
]osanetant(Antagonist)
(pK
d
9.9),[ 3H
]senktide
(Agonist)
[693]–
G
uinea
pig,[ 125I][M
ePhe 7]N
KB
(Agonist)
C
o
m
m
en
ts:
Th
e
N
K
1
receptor
h
as
also
been
described
to
couple
to
G
protein
s
oth
er
th
an
G
q/11
[1680].
Th
e
h
exapeptide
agon
ist
septide
appears
to
bin
d
to
an
overlappin
g
but
n
on
-iden
tical
site
to
substan
ce
P
(TA
C
1,
P20366)
on
th
e
N
K
1
receptor.
Th
ere
are
suggestion
s
for
addition
al
subtypes
of
tach
ykin
in
receptor;
an
orph
an
receptor
(Sw
issProt
P30098)
w
ith
structural
sim
ilarities
to
th
e
N
K
3
receptor
w
as
foun
d
to
respon
d
to
N
K
B
w
h
en
expressed
in
X
enopus
oocytes
or
C
h
in
ese
h
am
ster
ovary
cells
[459,1049].
Fu
rth
er
read
in
g
o
n
T
ach
yk
in
in
recep
to
rs
D
ouglas
SD
et
al.
(2011)
N
eurokin
in
-1
receptor:
fun
ction
al
sign
ifican
ce
in
th
e
im
m
un
e
system
in
referen
ce
to
selected
in
fection
s
an
d
in
flam
m
ation
.
A
nn.
N
.
Y.
A
cad.
Sci.
1217
:
83-95
[PM
ID
:21091716]
Foord
SM
etal.(2005)In
tern
ation
alU
n
ion
ofPh
arm
acology.X
LV
I.G
protein
-coupled
receptor
list.
Pharm
acolRev
57
:279-288
[PM
ID
:15914470]
Jon
es
S
et
al.
(2008)
Th
e
n
eurokin
in
1
receptor:
a
poten
tial
n
ew
target
for
an
ti-platelet
th
erapy?
C
urr
O
pin
Pharm
acol8
:114-9
[PM
ID
:18296119]
R
an
ce
N
E
et
al.
(2010)
N
eurokin
in
B
an
d
th
e
h
ypoth
alam
ic
regulation
of
reproduction
.
Brain
Res.
1364
:116-28
[PM
ID
:20800582]
R
ojas
C
et
al.
(2012)
Ph
arm
acological
m
ech
an
ism
s
of
5-H
T_3
an
d
tach
ykin
in
N
K
_1
receptor
an
-
tagon
ism
to
preven
t
ch
em
oth
erapy-in
duced
n
ausea
an
d
vom
itin
g.
Eur.
J.Pharm
acol.
684
:
1-7
[PM
ID
:22425650]
Stein
h
off
M
S
et
al.
(2014)
Tach
ykin
in
s
an
d
th
eir
receptors:
con
tribution
s
to
ph
ysiological
con
trol
an
d
th
e
m
ech
an
ism
s
of
disease.Physiol.Rev.94
:265-301
[PM
ID
:24382888]
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Thyrotropin-releasing
horm
one
receptors
G
protein
-coupled
receptors→
Th
yrotropin
-releasin
g
h
orm
on
e
receptors
O
verview
:
Th
yrotropin
-releasin
g
h
orm
on
e
(TR
H
)
receptors
(p
ro
visio
n
al
n
o
m
en
clatu
re
as
reco
m
m
en
d
ed
b
y
N
C
-IU
P
H
A
R
[557])
are
activated
by
th
e
en
dogen
ous
tripeptide
TR
H
(T
RH
,P20396)
(pG
lu-H
is-ProN
H
2).
TR
H
(T
RH
,
P20396)
an
d
TR
H
an
alogues
fail
to
distin
guish
TR
H
1
an
d
TR
H
2
receptors
[1896].
[ 3H
]TR
H
(h
um
an
,m
ouse,rat)
is
able
to
label
both
TR
H
1
an
d
TR
H
2
receptors
w
ith
K
d
values
of
13
an
d
9
n
M
respectively.
Syn
th
esis
an
d
biology
of
rin
g-m
odified
L-H
istidin
e
con
tain
in
g
TR
H
an
alogues
h
as
been
reported
[1316].
N
om
enclature
TRH
1
receptor
TRH
2
receptor
H
G
N
C
,U
niProt
TRH
R,P34981
–
Antagonists
diazepam
(pK
i 5.2)
[471]–
Rat
–
Selective
antagonists
m
idazolam
(pK
i 5.5)
[471]–
Rat,chlordiazepoxide
(pK
i 4.8)
[471]–
Rat,chlordiazepoxide
(pK
i 4.7)
[1878]–
M
ouse
–
C
om
m
ents
–
A
class
A
G
protein-coupled
receptor:not
present
in
m
an
Fu
rth
er
read
in
g
o
n
T
h
yro
tro
p
in
-releasin
g
h
o
rm
o
n
e
recep
to
rs
Bílek
R
etal.(2011)
TR
H
-like
peptides.
PhysiolRes
60
:207-15
[PM
ID
:21114375]
Foord
SM
etal.(2005)In
tern
ation
alU
n
ion
ofPh
arm
acology.X
LV
I.G
protein
-coupled
receptor
list.
Pharm
acolRev
57
:279-288
[PM
ID
:15914470]
N
illn
iEA
.(2010)
R
egulation
ofth
e
h
ypoth
alam
ic
th
yrotropin
releasin
g
h
orm
on
e
(TR
H
)
n
euron
by
n
euron
alan
d
periph
eralin
puts.FrontN
euroendocrinol31
:134-56
[PM
ID
:20074584]
Trace
am
ine
receptor
G
protein
-coupled
receptors→
Trace
am
in
e
receptor
O
verview
:
Trace
am
in
e-associated
receptors
w
ere
discovered
from
a
search
for
n
ovel
5-H
T
receptors
[189],
w
h
ere
15
m
am
-
m
alian
orth
ologues
w
ere
iden
tified
an
d
divided
in
to
tw
o
fam
-
ilies.
Th
e
TA
1
receptor
(n
o
m
en
clatu
re
as
ag
reed
b
y
th
e
N
C
-IU
P
H
A
R
Su
b
co
m
m
ittee
fo
r
th
e
T
race
am
in
e
recep
to
r
[1244])
h
as
affin
ity
for
th
e
en
dogen
ous
trace
am
in
es
tyram
in
e,
β-ph
en
yleth
ylam
in
e
an
d
octopam
in
e
in
addition
to
th
e
classi-
cal
am
in
e
dopam
in
e
[189].
Em
ergin
g
eviden
ce
suggests
th
at
TA
1
is
a
m
odulator
of
m
on
oam
in
ergic
activity
in
th
e
brain
[2151]
w
ith
TA
1
an
d
dopam
in
e
D
2
receptors
sh
ow
n
to
form
con
stitu-
tive
h
eterodim
ers
w
h
en
co-expressed
[519].
In
addition
to
trace
am
in
es,receptors
can
be
activated
by
am
ph
etam
in
e-like
psych
os-
tim
ulan
ts,an
d
en
dogen
ous
th
yron
am
in
es.
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N
om
enclature
TA
1
receptor
H
G
N
C
,U
niProt
TAAR1,Q
96RJ0
Potency
order
ofendogenous
ligands
tyram
ine
>
β-phenylethylam
ine
>
octopam
ine
=
dopam
ine
[189]
Agonists
RO
5166017
[1648]
Antagonists
EPPTB
(Inverse
agonist)
(pIC
50
5.1)
[205]
Labelled
ligands
[ 3H
]tyram
ine
(Agonist)
[189]
C
o
m
m
en
ts:
In
addition
to
TA
1 ,
in
m
an
th
ere
are
up
to
5
fun
c-
tion
al
TA
A
R
gen
es
(TA
A
R
2,5,6,8,9).
See
[189]
for
detailed
discus-
sion
.
Th
e
product
of
th
e
gen
e
TA
A
R
2
(also
kn
ow
n
as
G
PR
58)
appearsto
respon
d
to
β-ph
en
yleth
ylam
in
e
>
tyram
in
e
an
d
to
cou-
ple
th
rough
G
s
[189].
TA
A
R3,
in
som
e
in
dividuals,
an
d
TA
A
R4
are
pseudogen
es
in
m
an
,alth
ough
fun
ction
alin
roden
ts.Th
e
sig-
n
allin
g
ch
aracteristics
an
d
ph
arm
acology
ofTA
A
R
5
(PN
R
,Putative
N
eurotran
sm
itterR
eceptor:TA
A
R5,O
14804),TA
A
R
6
(Trace
am
in
e
receptor
4,
TaR
-4:
TA
A
R6,
96R
I8),
TA
A
R
8
(Trace
am
in
e
receptor
5,G
PR
102:
TA
A
R8,Q
969N
4
)
an
d
TA
A
R
9
(trace
am
in
e
associated
receptor
9:
TA
A
R
9,
96R
I9)
are
lackin
g.
Th
e
th
yron
am
in
es,
en
-
dogen
ous
derivatives
ofth
yroid
h
orm
on
e,h
ave
affin
ity
forroden
t
clon
ed
trace
am
in
e
receptors,in
cludin
g
TA
1
[1728].A
n
an
tagon
ist
EPPTB
h
as
recen
tly
been
described
w
ith
a
pK
i of
9.1
at
th
e
m
ouse
TA
1
but
>
5.3
for
h
um
an
TA
1
[1863].
Fu
rth
er
read
in
g
o
n
T
race
am
in
e
recep
to
r
M
aguire
JJ
et
al.
(2009)
In
tern
ation
al
U
n
ion
of
Ph
arm
acology.
LX
X
II.R
ecom
m
en
dation
s
for
trace
am
in
e
receptor
n
om
en
clature.
Pharm
acol.Rev.61
:1-8
[PM
ID
:19325074]
PeiY
etal.(2016)Trace
A
m
in
es
an
d
th
e
Trace
A
m
in
e-A
ssociated
R
eceptor
1:Ph
arm
acology,N
euro-
ch
em
istry,an
d
C
lin
icalIm
plication
s.
FrontN
eurosci10
:148
[PM
ID
:27092049]
U
rotensin
receptor
G
protein
-coupled
receptors→
U
roten
sin
receptor
O
verview
:
Th
e
uroten
sin
-II
(U
-II)
receptor
(U
T,
n
o
m
en
cla-
tu
re
as
ag
reed
b
y
th
e
N
C
-IU
P
H
A
R
Su
b
co
m
m
ittee
o
n
th
e
U
ro
ten
sin
recep
to
r
[466,
557,
2032])
is
activated
by
th
e
en
-
dogen
ous
dodecapeptide
uroten
sin
-II
(U
T
S2,
O
95399),
origin
ally
isolated
from
th
e
uroph
ysis,
th
e
en
docrin
e
organ
of
th
e
caudal
n
eurosecretory
system
of
teleost
fish
[138].
Several
structural
form
s
of
U
-II
exist
in
fish
an
d
am
ph
ibian
s.
Th
e
goby
orth
ologue
w
as
used
to
iden
tify
U
-II
as
th
e
cogn
ate
ligan
d
for
th
e
predicted
receptor
en
coded
by
th
e
rat
gen
e
gpr14
[389,
1195,
1379,
1476].
H
um
an
uroten
sin
-II
(U
T
S2,
O
95399),
an
11-am
in
o-acid
peptide
[389],
retain
s
th
e
cycloh
exapeptide
sequen
ce
of
goby
U
-II
th
at
is
th
ough
t
to
be
im
portan
t
in
ligan
d
bin
din
g
[224,
1003].
Th
is
sequen
ce
is
also
con
served
in
th
e
deduced
am
in
o-acid
sequen
ce
of
rat
uroten
sin
-II
{R
at}
(14
am
in
o-acids)
an
d
m
ouse
uroten
sin
-II
{M
ouse}
(14
am
in
o-acids),
alth
ough
th
e
N
-term
in
al
is
m
ore
di-
vergen
t
from
th
e
h
um
an
sequen
ce
[388].
A
secon
d
en
dogen
ous
ligan
d
for
th
e
U
T
h
as
been
discovered
in
rat
[1890].
Th
is
is
th
e
uroten
sin
II-related
peptide
(U
T
S2B,Q
765I0),an
octapeptide
th
at
is
derived
from
a
differen
t
gen
e,
but
sh
ares
th
e
C
-term
in
al
se-
quen
ce
(C
FW
K
Y
C
V
)com
m
on
to
U
-IIfrom
oth
erspecies.Iden
tical
sequen
ces
to
rat
uroten
sin
II-related
peptide
(U
T
S2B,Q
765I0)
are
predicted
forth
e
m
ature
m
ouse
an
d
h
um
an
peptides
[472].U
T
ex-
h
ibits
relatively
h
igh
sequen
ce
iden
tity
w
ith
som
atostatin
,opioid
an
d
galan
in
receptors
[2032].
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N
om
enclature
U
T
receptor
H
G
N
C
,U
niProt
U
TS2R,Q
9U
KP6
Endogenous
agonists
urotensin
II-related
peptide
(U
TS2B,Q
765I0)
[472,1243],urotensin-II(U
TS2,O
95399)
[467,503,681]
Selective
agonists
[Pen
5]U
-(4-11)
(hum
an)
[681],U
-II-(4-11)
(hum
an)
[681],[3-iodo-Tyr 6]U
-II-(4-11)
(hum
an)
[1084],U
rolinin
[95],FL104
[1139,1141],AC
-7954
[398,1140]
Selective
antagonists
JN
J-39319202
(pK
i 8.4)
[1106],urantide
(pK
i 8.3)
[1536],SB-706375
(pK
i 8)
[467],[O
rn
5]U
RP
(pK
i 7.2)
[445]–
Rat,palosuran
(pIC
50
7.1)
[366],SB-436811
(pK
i 6.7)
[912]–
Rat,
SB-611812
(pK
i 6.6)
[1622],S6716
(Inverse
agonist)
(pIC
50
6.4)
[554],[C
ha 6]U
-II-(4-11)
(pK
i 6.4)
[312]–
Rat
Labelled
ligands
[ 125I]U
-II(hum
an)
(Agonist)
[42,198,312,1243],[ 125I]N
-biotin-[Ahx 0,Bpa 3]U
-II(hum
an)
[454]
C
o
m
m
en
ts:In
th
e
h
um
an
vasculature,h
um
an
uroten
sin
-II
(U
T
S2,O
95399)
elicits
both
vasocon
strictor
(pD
2
9.3-10.1,[1243])
an
d
vasodilator
(pIC
50
10.3-10.4,[1872])
respon
ses.
Fu
rth
er
read
in
g
o
n
U
ro
ten
sin
recep
to
r
Foord
SM
etal.(2005)In
tern
ation
alU
n
ion
ofPh
arm
acology.X
LV
I.G
protein
-coupled
receptor
list.
Pharm
acolRev
57
:279-288
[PM
ID
:15914470]
H
un
t
BD
et
al.
(2010)
A
rat
brain
atlas
of
uroten
sin
-II
receptor
expression
an
d
a
review
of
cen
tral
uroten
sin
-II
effects.
N
aunyn
Schm
iedebergs
A
rch.Pharm
acol.382
:1-31
[PM
ID
:20422157]
M
aryan
off
BE
et
al.
(2010)
U
roten
sin
-II
receptor
m
odulators
as
poten
tial
drugs.
J.M
ed.
C
hem
.
53
:
2695-708
[PM
ID
:20043680]
R
oss
B
et
al.
(2010)
R
ole
of
uroten
sin
II
in
h
ealth
an
d
disease.
A
m
.
J.Physiol.
Regul.
Integr.
C
om
p.
Physiol.298
:R
1156-72
[PM
ID
:20421634]
Vasopressin
and
oxytocin
receptors
G
protein
-coupled
receptors→
V
asopressin
an
d
oxytocin
receptors
O
verview
:V
asopressin
(AV
P)an
d
oxytocin
(O
T)receptors
(n
o
m
en
clatu
re
as
reco
m
m
en
d
ed
b
y
N
C
-IU
P
H
A
R
[557])are
activated
by
th
e
en
dogen
ous
cyclic
n
on
apeptides
vasopressin
(AV
P,P01185)
an
d
oxytocin
(O
X
T
,P01178).Th
ese
peptides
are
derived
from
precursors
w
h
ich
also
produce
n
europh
ysin
s
(n
europh
ysin
I
for
oxytocin
;n
europh
ysin
II
for
vasopressin
).
N
om
enclature
V
1A
receptor
V
1B
receptor
H
G
N
C
,U
niProt
AVPR1A,P37288
AVPR1B,P47901
Potency
order
ofendogenous
ligands
vasopressin
(AVP,P01185)
>
oxytocin
(O
XT,P01178)
vasopressin
(AVP,P01185)
>
oxytocin
(O
XT,P01178)
Endogenous
agonists
vasopressin
(AVP,P01185)
[24,326,383,439,1418,1571,1702,1913,1914,1945,1946,2162]
vasopressin
(AVP,P01185)
[24,326,439,682,1418,
1702,1913,1914,1946,2162]
Selective
agonists
F180
[50,383]
d[Leu
4]LVP
[1553],d[C
ha 4]AVP
[439,682]
Antagonists
conivaptan
(pK
i 8.2–8.4)
[1913,1914]
nelivaptan
(pK
i 8.4–9.3)
[678,682,1773]
Selective
antagonists
relcovaptan
(pK
i 8.1–9.3)
[24,383,682,1571,1771,1913,1945,1946,1986],
d(C
H
2 )5 [Tyr(M
e) 2,Arg
8]VP
(pK
i 9)
–
Searchable
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N
om
enclature
V
1A
receptor
V
1B
receptor
Labelled
ligands
[ 125I]O
H
-LVA
(Antagonist)
(pK
d
10.3–10.4)
[334,383,1571],[ 3H
]AVP
(hum
an,m
ouse,rat)
(Agonist)
[214,334,383,384,1418,1571,1702,1913,1914,1945,1946,1986,2162],
[ 3H
]d(C
H
2 )5 [Tyr(M
e) 2]AVP
(Antagonist)
(pK
d
9)
[ 3H
]AVP
(hum
an,m
ouse,rat)
(Agonist)
[214,334,383,
384,1418,1571,1702,1913,1914,1945,1946,1986,
2162]
N
om
enclature
V
2
receptor
O
T
receptor
H
G
N
C
,U
niProt
AVPR2,P30518
O
XTR,P30559
Potency
order
ofendogenous
ligands
vasopressin
(AVP,P01185)
>
oxytocin
(O
XT,P01178)
oxytocin
(O
XT,P01178)
>
vasopressin
(AVP,P01185)
Endogenous
agonists
vasopressin
(AVP,P01185)
[24,326,334,439,1418,1702,1771,1913,1914,1946,2162]
oxytocin
(O
XT,P01178)
[24,334,335,360,682,895]
Selective
agonists
VN
A932
[527],O
PC
-51803
[1418],d[Val 4,D
Arg
8]VP
[Thr 4,G
ly 7]O
T
[335,500,895]
Antagonists
–
L-371,257
(pK
i 8.8)
[682]
Selective
antagonists
conivaptan
(pK
i 9.4)
[397],tolvaptan
(pK
i 9.4)
[2162],satavaptan
(pK
i 8.4–9.3)
[24,383,384,
1770,1771,1913,1986],lixivaptan
(Inverse
agonist)
(pK
i 8.9–9.2)
[33,1771],
d(C
H
2 )5 [D
-Ile 2,Ile 4]AVP
(pK
i 6.9–8.4)
[1771],m
ozavaptan
(Inverse
agonist)
(pK
i 7.4–8.1)
[384,
1771,1913,1946,2162,2163]
SSR126768A
(pK
i 8.8–9.1)
[1772],
desG
lyN
H
2 -d(C
H
2 )5 [Tyr(M
e) 2,Thr 4,O
rn
8]O
T
(pK
i 8.5),
L-372662
(pK
i 8.4)
[127]
Labelled
ligands
[ 3H
]AVP
(hum
an,m
ouse,rat)
(Agonist)
[334,383,384,1418,1702,1913,1914,1946,1986,
2162],[ 3H
]dD
AVP
(Agonist)
[334,384,1946],[ 3H
]desG
ly-N
H
2 [D
-Ile 2,Ile 4]VP
(pK
d
8.6)
[ 125I]d(C
H
2 )5 [Tyr(M
e) 2,Thr 4,O
rn
8,Tyr-N
H
2
9]O
VT
(Antagonist)
(pK
d
10),[ 3H
]O
T
(hum
an,m
ouse,rat)
(Agonist)
[334,583,
895,998],[ 111In]D
O
TA-dLVT
(pK
d
8.3)
[333]
C
o
m
m
en
ts:
Th
e
V
2
receptor
exh
ibits
m
arked
species
differen
ces,such
th
at
m
an
y
ligan
ds
(d(C
H
2 )5 [D
-Ile 2,Ile 4]AV
P
an
d
[ 3H
]desG
ly-N
H
2 [D
-Ile 2,Ile 4]V
P)
exh
ibit
low
affin
ity
at
h
um
an
V
2
receptors
[29].
Sim
ilarly,[ 3H
]d[D
-A
rg
8]V
P
is
V
2
selective
in
th
e
rat,n
ot
in
th
e
h
um
an
[1702].
Th
e
gen
e
en
codin
g
th
e
V
2
receptor
is
polym
orph
ic
in
m
an
,un
derlyin
g
n
eph
rogen
ic
diabetes
in
sipidus
[152].
D
[C
h
a 4]AV
P
is
selective
on
ly
for
th
e
h
um
an
an
d
bovin
e
V
1B
receptors
[439],w
h
ile
d[Leu
4]LV
P
h
as
h
igh
affin
ity
for
th
e
rat
V
1B
receptor
[1553].
Fu
rth
er
read
in
g
o
n
V
aso
p
ressin
an
d
o
x
yto
cin
recep
to
rs
Bartz
JA
etal.(2011)
Socialeffects
ofoxytocin
in
h
um
an
s:con
text
an
d
person
m
atter.Trends
C
ogn.
Sci.(Regul.Ed.)
15
:301-9
[PM
ID
:21696997]
K
n
epper
M
A
.(2012)
System
s
biology
in
ph
ysiology:
th
e
vasopressin
sign
alin
g
n
etw
ork
in
kidn
ey.
A
m
.J.Physiol.,C
ellPhysiol.303
:C
1115-24
[PM
ID
:22932685]
K
osh
im
izu
TA
et
al.
(2012)
V
asopressin
V
1a
an
d
V
1b
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VIP
and
PAC
AP
receptors
G
protein
-coupled
receptors→
V
IP
an
d
PA
C
A
P
receptors
O
verview
:
V
asoactive
in
testin
al
peptide
(V
IP)
an
d
pituitary
aden
ylate
cyclase-activatin
g
peptide
(PA
C
A
P)
receptors
(n
o
m
en
-
clatu
re
as
ag
reed
b
y
th
e
N
C
-IU
P
H
A
R
Su
b
co
m
m
ittee
o
n
V
aso
active
In
testin
al
P
ep
tid
e
R
ecep
to
rs
[739,740])are
ac-
tivated
by
th
e
en
dogen
ous
peptides
V
IP
(V
IP,P01282),PA
C
A
P-38
(A
D
C
YA
P1,P18509),PA
C
A
P-27
(A
D
C
YA
P1,P18509),peptide
h
is-
tidin
e
isoleucin
eam
ide
(PH
I
{M
ouse,
R
at}),
peptide
h
istidin
e
m
e-
th
ion
in
eam
ide
(PH
M
(V
IP,
P01282))
an
d
peptide
h
istidin
e
va-
lin
e
(PH
V
(V
IP,
P01282)).
V
PA
C
1
an
d
V
PA
C
2
receptors
dis-
play
com
parable
affin
ity
for
th
e
PA
C
A
P
peptides,
PA
C
A
P-27
(A
D
C
YA
P1,
P18509)
an
d
PA
C
A
P-38
(A
D
C
YA
P1,
P18509),
an
d
V
IP
(V
IP,
P01282),
w
h
ereas
PA
C
A
P-27
(A
D
C
YA
P1,
P18509)
an
d
PA
C
A
P-38
(A
D
C
YA
P1,
P18509)
are
>
100
fold
m
ore
poten
t
th
an
V
IP
(V
IP,
P01282)
as
agon
ists
of
m
ost
isoform
s
of
th
e
PA
C
1
re-
ceptor.
H
ow
ever,on
e
splice
varian
t
of
th
e
h
um
an
PA
C
1
receptor
h
as
been
reported
to
respon
d
to
PA
C
A
P-38
(A
D
C
YA
P1,
P18509),
PA
C
A
P-27
(A
D
C
YA
P1,
P18509)
an
d
V
IP
(V
IP,
P01282)
w
ith
com
-
parable
affin
ity
[411].
PG
99-465
[1374]
h
as
been
used
as
a
selec-
tive
V
PA
C
2
receptoran
tagon
istin
a
n
um
berofph
ysiologicalstud-
ies,
but
h
as
been
reported
to
h
ave
sign
ifican
t
activity
at
V
PA
C
1
an
d
PA
C
1
receptors
[446].
Th
e
selective
PA
C
1
receptor
agon
ist
m
axadilan
,
w
as
extracted
from
th
e
salivary
glan
ds
of
san
d
flies
(Lutzom
yia
longipalpis)an
d
h
asn
o
sequen
ce
h
om
ology
to
V
IP
(V
IP,
P01282)
or
th
e
PA
C
A
P
peptides
[1383].
Tw
o
deletion
varian
ts
of
m
axadilan
,M
65
[1994]an
d
M
ax.d.4
[1384]h
ave
been
reported
to
be
PA
C
1
receptor
an
tagon
ists,
but
th
ese
peptides
h
ave
n
ot
been
exten
sively
ch
aracterised.
N
om
enclature
PAC
1
receptor
VPAC
1
receptor
VPAC
2
receptor
H
G
N
C
,U
niProt
AD
CYAP1R1,P41586
VIPR1,P32241
VIPR2,P41587
Potency
order
ofendogenous
ligands
PAC
AP-27
(AD
CYAP1,P18509),
PAC
AP-38
(AD
CYAP1,P18509)≫
VIP
(VIP,P01282)
VIP
(VIP,P01282),PAC
AP-27
(AD
CYAP1,P18509),PAC
AP-38
(AD
CYAP1,P18509)≫
G
H
RH
(G
H
RH
,P01286),PH
I{Pig},
secretin
(SCT,P09683)
VIP
(VIP,P01282),PAC
AP-38
(AD
CYAP1,P18509),PAC
AP-27
(AD
CYAP1,P18509)
>
PH
I{Pig}≫
G
H
RH
(G
H
RH
,P01286),
secretin
(SCT,P09683)
Selective
agonists
m
axadilan
[446],m
axadilan
[446]
[Lys 15,Arg
16,Leu
27]VIP-(1-7)/G
RF-(8-27)-N
H
2
[1369],
[Ala 11,22,28]VIP
[1458]
Ro
25-1553
[669,930,1369],Ro
25-1392
[2144]
Selective
antagonists
–
PG
97-269
(pIC
50
8.7)
[668,930]
–
Labelled
ligands
[ 125I]PAC
AP-27
(Agonist)
[1581]
[ 125I]VIP
(hum
an,m
ouse,rat)
(Agonist)
[1458],
[ 125I]PAC
AP-27
(Agonist)
[ 125I]VIP
(hum
an,m
ouse,rat)
(Agonist)
[1458],
[ 125I]PAC
AP-27
(Agonist)
C
o
m
m
en
ts:
Subtypes
of
PA
C
1
receptors
h
ave
been
proposed
based
on
tissue
differen
ces
in
th
e
poten
cies
of
PA
C
A
P-27
(A
D
C
YA
P1,P18509)
an
d
PA
C
A
P-38
(A
D
C
YA
P1,P18509);th
ese
m
igh
t
result
from
differen
ces
in
G
protein
couplin
g
an
d
secon
d
m
essen
ger
m
ech
an
ism
s
[2018],or
from
altern
ative
splicin
g
of
PA
C
1
receptor
m
R
N
A
[1859].
Fu
rth
er
read
in
g
o
n
V
IP
an
d
PA
C
A
P
recep
to
rs
H
arm
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Jetal.(1998)In
tern
ation
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n
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ofPh
arm
acology.X
V
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om
en
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ofreceptors
for
vasoactive
in
testin
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an
d
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aden
ylate
cyclase-activatin
g
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acol
Rev
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[PM
ID
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ID
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